Page last updated: 2024-12-04

bisacodyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID2391
CHEMBL ID942
CHEBI ID3125
SCHEMBL ID21044
MeSH IDM0002606

Synonyms (286)

Synonym
AB00051928-17
BRD-K39987650-001-05-0
NSC614826 ,
phenol,4'-(2-pyridinylmethylene)bis-, diacetate (ester)
bisacodyl, active ingredient of viraplex
nsc-614826
mls002701749 ,
bisacodyl
4,4'-diacetoxydiphenylpyridyl-2-methane
MLS000069729 ,
DIVK1C_000347
KBIO1_000347
NCI60_004954
NCIMECH_000456
NCICHAL_000004
(pyridin-2-ylmethylene)di-4,1-phenylene diacetate
evac-q-tabs
phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate (ester)
durolax
neolax
sanvacual
4,4'-(2-pyridylmethylene)diphenol diacetate (ester)
phenol, 4,4'-(2-pyridylmethylene)di-, diacetate (ester)
endokolat
4,4'-(2-pyridylmethylene)diphenol diacetate
pyrilax
telemin
dulcolan
eulaxan
di-(p-acetoxyphenyl)-2-pyridylmethane
hillcolax
einecs 210-044-4
laxadin
di-(4-acetoxyphenyl)-2-pyridylmethane
2-(4,4'-diacetoxydiphenylmethyl)pyridine
brn 0323727
fenilaxan
la96a
zetrax
stadalax
theralax
laxine
hsdb 3016
halflytely
laxans
(4,4'-diacetoxydiphenyl)(2-pyridyl)methane
bisacodilo [inn-spanish]
bisacodylum [inn-latin]
nigalax
laxorex
godalax
bis(p-acetoxyphenyl)-2-pyridylmethane
deficol
ulcolax
laco
sk-bisacodyl
dulcolax
bicol
laxanin n
brocalax
ivilax
SPECTRUM_000086
PRESTWICK2_000419
IDI1_000347
PRESTWICK_780
603-50-9
NCGC00016522-01
cas-603-50-9
BSPBIO_000378
SPECTRUM5_000898
BPBIO1_000416
NCGC00023260-03
AB00051928
modane
(pyridin-2-ylmethanediyl)dibenzene-4,1-diyl diacetate
STK293202
bisacodyl (jp17/usp/inn)
dulcolax (tn)
D00245
PRESTWICK3_000419
NCGC00023260-05
NCGC00023260-04
smr000058226
KBIOSS_000506
KBIO3_001416
KBIOGR_000692
KBIO2_000506
KBIO2_003074
KBIO2_005642
SPECTRUM3_000318
SPBIO_000258
SPECTRUM2_000149
SPECTRUM4_000256
NINDS_000347
PRESTWICK0_000419
PRESTWICK1_000419
SPBIO_002317
SPECTRUM1500147
BSPBIO_001916
NCGC00016522-02
HMS2091O03
HMS2090K15
CHEMBL942
nsc-755914
HMS501B09
HMS1569C20
HMS1920G21
[4-[(4-acetyloxyphenyl)-pyridin-2-ylmethyl]phenyl] acetate
NCGC00016522-05
A832704
[4-[(4-acetoxyphenyl)-(2-pyridyl)methyl]phenyl] acetate;bisacodyl
AKOS001599884
NCGC00023260-06
HMS2096C20
NCGC00257892-01
tox21_200338
nsc755914
pharmakon1600-01500147
dtxsid1022681 ,
tox21_110472
dtxcid202681
HMS2235I11
S4047
CCG-35661
CCG-36442
NCGC00016522-03
NCGC00016522-10
NCGC00016522-12
NCGC00016522-06
NCGC00016522-11
NCGC00016522-04
NCGC00016522-09
NCGC00016522-08
NCGC00016522-07
bisacodyl [usp:inn:ban:jan]
ccris 8864
phenol, 4,4'-(2-pyridinylmethylene)bis-, 1,1'-diacetate
correctol tablets, caplets
feen-a-mint tablets
bisacodylum
bisacodilo
10x0709y6i ,
unii-10x0709y6i
nsc 755914
FT-0603486
bisacodyl [usp-rs]
bisacodyl [vandf]
bisacodyl [inn]
bisacodyl [ep monograph]
bisacodyl [hsdb]
halflytely component bisacodyl
bisacodyl [mi]
bisacodyl [mart.]
bisacodyl [who-dd]
bisacodyl [orange book]
bisacodyl [usp monograph]
bisacodyl [jan]
bisacodyl component of halflytely
HMS3373L17
HY-B0557
SCHEMBL21044
tox21_110472_1
(pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate
Q-200727
Q-200726
cid_2391
bdbm61400
4,4'-diacetoxydiphenylpyrid-2-ylmethane
4-[[4-(acetyloxy)phenyl](2-pyridinyl)methyl]phenyl acetate #
phenol, 4,4'-(2-pyridylmethylene)di-, diacetate
halflytely (salt/mix)
phenol, 4,4'-(2-pyridinylmethylene)bis-, diacetate
AC-24284
AB00051928_18
OPERA_ID_884
AB00051928_19
REGID_FOR_CID_2391
mfcd00038039
DB09020
broxalax
bisacodyl, analytical standard, for drug analysis
bisacodyl, european pharmacopoeia (ep) reference standard
4,4'-(2-pyridylmethylene)bisphenol diacetate
sr-01000000233
SR-01000000233-2
bisacodyl, united states pharmacopeia (usp) reference standard
HMS3652E04
bisacodyl for system suitability, european pharmacopoeia (ep) reference standard
bisacodyl for peak identification, european pharmacopoeia (ep) reference standard
SR-01000000233-3
CHEBI:3125
SBI-0051297.P003
HMS3713C20
4-{[4-(acetyloxy)phenyl](pyridin-2-yl)methyl}phenyl acetate
SW196918-3
BCP18567
Q417874
4,4'-(pyridin-2-ylmethylene)bis(4,1-phenylene) diacetate
bisacodyl,(s)
bisacodyl 100 microg/ml in acetonitrile
AS-15820
B5066
BRD-K39987650-001-15-9
A14914
horton
D81813
bisacodyl for system suitability
bisacodyl for peak identification
phenol,4,4'-(2-pyridinylmethylene)bis-,1,1'-diacetate
EN300-7405275
the medicine shoppe gentle laxative
womens laxative enteric coated
bisacodil
a06ab02
dulcolax pink stimulant laxative
unit dose bisacodyl
dulcolax stimulant laxative
foster and thrive gentle laxative
cvs gentle laxative
p lax dr
bisacodylenteric coated
discount drugmart gentle laxative
bisac-10 bisacodyl stimulant laxative
bisacodyle
stratuscare bisacodyl
womans laxative
leader womens laxative
bisacodylstimulant laxative
the magic bullet
gentle laxativestimulant laxative
bisacodyl enteric
bisacodyl 5mg
bisacodyl (ep monograph)
delayed release laxative bisacodyl
heb gentle laxative
gentle laxative bisacodyl
bisacodyl (usp monograph)
meijer gentle laxative
good neighbor pharmacy gentle laxative
publix women
womens laxative
avedana gentle laxative
bisacody
carters little pillssodium-free
onelax
enteric coated stimulant laxative
best choice bisacodyl laxative
rugby gentle laxative
bisacodyl laxative
biscodyl
carters little pills
laxative for women
bet-r-prep bisacodyl
leader gentle laxative
c-lax laxative
premier value bisacodyl laxative
rite aid fast relief laxative
y lax dr
a06ag02
medique medi-lax enteric coated
stimulant laxative enteric coated
bisacodyl (mart.)
extra gentle laxative
4,4'-(pyridin-2-ylmethylene)bis(phenyl acetate)
conlax
bisacodyl (usp-rs)
simpex bisacodyl laxative
dollar general gentle laxative
dulcolax simulant laxative
gentle overnight laxative
womens gentle laxative
walgreens gentle laxative
dulcolax laxative
laxativegentle
up and up gentle laxative
laxativeenteric coated
bisacodyl suppository
bisacodyl laxativeenteric coated
laxativewomen
topcare gentle laxative
healthmart gentle laxative
biisacodyl
publixstimulant laxative
publix womenlaxative
bisacodyl 5 mg
bisacodyenteric coated

Research Excerpts

Overview

Bisacodyl is a member of the diphenylmethane family and is considered to be a stimulant laxative. It is an effective treatment for patients with chronic constipation.

ExcerptReferenceRelevance
"Bisacodyl is a member of the diphenylmethane family and is considered to be a stimulant laxative. "( Bisacodyl: A review of pharmacology and clinical evidence to guide use in clinical practice in patients with constipation.
Corsetti, M; Landes, S; Lange, R, 2021
)
3.51
"Bisacodyl is a stimulant laxative often used in manometric studies of pediatric constipation to determine if it can initiate propulsive high-amplitude propagating contractions (HAPCs). "( Duodenal and proximal jejunal motility inhibition associated with bisacodyl-induced colonic high-amplitude propagating contractions.
Amicangelo, M; Brookes, SJH; Costa, M; Dinning, PG; Nurko, S; Whitter, L; Wiklendt, L, 2021
)
2.3
"Oral bisacodyl is an effective and well-tolerated treatment for patients with chronic constipation. "( Oral bisacodyl is effective and well-tolerated in patients with chronic constipation.
Gessner, U; Kamm, MA; Mueller-Lissner, S; Richter, E; Swallow, R; Wald, A, 2011
)
1.4

Treatment

Bisacodyl treatment can relieve STC symptoms, which may be associated with increased ICC number and c-Kit protein expression. Treatment had no effect on plasma K+ concentrations in control subjects, but significantly decreased the mean interdialytic Plasma K+ concentration (from 5.9+/-0.2 to 5.5+/- 0.2 mmol/l) in haemodialysis patients.

ExcerptReferenceRelevance
"Bisacodyl treatment can relieve STC symptoms, which may be associated with increased ICC number and c-Kit protein expression."( [Experimental study of Bisacodyl in the treatment of slow transit constipation model rats].
Ling, J; Qiu, W; Wang, Y; Xu, B; Zhang, W, 2016
)
2.19
"Bisacodyl treatment had no effect on plasma K+ concentrations in control subjects, but significantly decreased the mean interdialytic plasma K+ concentration (from 5.9+/-0.2 to 5.5+/-0.2 mmol/l, P<0.0005) in haemodialysis patients, whereas plasma K+ concentration did not change during lactulose treatment."( Dietary potassium and laxatives as regulators of colonic potassium secretion in end-stage renal disease.
Mathialahan, T; Sandle, GI, 2003
)
1.04
"Treatment with bisacodyl was well-tolerated."( Oral bisacodyl is effective and well-tolerated in patients with chronic constipation.
Gessner, U; Kamm, MA; Mueller-Lissner, S; Richter, E; Swallow, R; Wald, A, 2011
)
1.22

Toxicity

Bisacodyl is effective and safe in improving stool frequency and consistency in acute treatment of idiopathic constipation. A 2-day bowel preparation with PEG and bisacodyr is safe, effective, and well accepted for colonoscopy in children without any major adverse effects.

ExcerptReferenceRelevance
" Patients recorded stool frequency and consistency and adverse events."( Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study.
Jordan, CC; Kamm, MA; Kienzle-Horn, S; Peil, H; Schuijt, C; Vix, JM, 2006
)
0.64
"Bisacodyl is effective and safe in improving stool frequency and consistency in acute treatment of idiopathic constipation."( Efficacy and safety of bisacodyl in the acute treatment of constipation: a double-blind, randomized, placebo-controlled study.
Jordan, CC; Kamm, MA; Kienzle-Horn, S; Peil, H; Schuijt, C; Vix, JM, 2006
)
2.09
" Safety assessments included recording of adverse events and changes in biochemical tests and vital signs."( A randomized, multicenter study comparing the safety and efficacy of sodium phosphate tablets with 2L polyethylene glycol solution plus bisacodyl tablets for colon cleansing.
Carter, E; Cohen, LB; Forbes, WP; Johanson, JF; Lottes, SR; Popp, JW; Rose, M; Walker, K; Zhang, B, 2007
)
0.54
" The 32-tablet NaP dosing regimen was associated with fewer adverse events."( A randomized, multicenter study comparing the safety and efficacy of sodium phosphate tablets with 2L polyethylene glycol solution plus bisacodyl tablets for colon cleansing.
Carter, E; Cohen, LB; Forbes, WP; Johanson, JF; Lottes, SR; Popp, JW; Rose, M; Walker, K; Zhang, B, 2007
)
0.54
" Stool frequency, consistency, and adverse effects were monitored for the duration of the bowel preparation."( Two-day bowel preparation with polyethylene glycol 3350 and bisacodyl: a new, safe, and effective regimen for colonoscopy in children.
Husain, SZ; Johnson, S; Pashankar, DS; Phatak, UP, 2011
)
0.61
" Adverse effects were mild nausea (19%), abdominal pain (11%), and vomiting (4%)."( Two-day bowel preparation with polyethylene glycol 3350 and bisacodyl: a new, safe, and effective regimen for colonoscopy in children.
Husain, SZ; Johnson, S; Pashankar, DS; Phatak, UP, 2011
)
0.61
"A 2-day bowel preparation with PEG and bisacodyl is safe, effective, and well accepted for colonoscopy in children without any major adverse effects."( Two-day bowel preparation with polyethylene glycol 3350 and bisacodyl: a new, safe, and effective regimen for colonoscopy in children.
Husain, SZ; Johnson, S; Pashankar, DS; Phatak, UP, 2011
)
0.88
" No medication-related adverse events were reported."( Efficacy and Safety of Sodium Picosulfate/Magnesium Citrate for Bowel Preparation in a Physically Disabled Outpatient Population: A Randomized, Endoscopist-Blinded Comparison With Ascorbic Acid-Enriched Polyethylene Glycol Solution Plus Bisacodyl (The PIC
Mathus-Vliegen, EMH; Stadwijk, JS; van der Vliet, K; Wignand-van der Storm, IJ, 2018
)
0.66
"There were no significant differences in compliance rates, adverse effects, and extent of colonoscopic evaluation."( [Tolerance, safety and efficacy of the one-day preparation of PEG3350 + bisacodyl compared to 2 days of PEG3350 + bisacodyl in pediatric patients].
Blanco Rodriguez, G; Penchyna Grub, J; Portillo Canizalez, LM; Teyssier Morales, G; Trauernicht Mendieta, S; Zurita-Cruz, JN,
)
0.36
" Diarrhea, nausea, bloating, and abdominal pain were common adverse events, but no serious adverse events were reported."( Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review.
Brenner, DM; Rao, SSC, 2021
)
0.62

Compound-Compound Interactions

Study was to compare oral intake of sodium phosphate solution (SP) with a conventional method of bowel preparation using Bisacodyl combined with repeated water enemas.

ExcerptReferenceRelevance
"Two hundred and ninety-one adults scheduled for routine sigmoidoscopy were randomly assigned to receive one of three preparations containing oral magnesium citrate (296 cc) taken the night before the procedure in combination with the following: 1) oral bisacodyl (10 mg), given with the magnesium citrate the night before the procedure; 2) one hypertonic phosphate enema 1 h before the procedure; or 3) two hypertonic phosphate enemas, given singly at 2 and 1 h before the procedure."( A comparison of bowel preparations for flexible sigmoidoscopy: oral magnesium citrate combined with oral bisacodyl, one hypertonic phosphate enema, or two hypertonic phosphate enemas.
Fincher, RK; Jackson, JL; Osgard, EM; Strong, JS; Wong, RK, 1999
)
0.7
" The aim of this study was to compare oral intake of sodium phosphate solution (SP) with a conventional method of bowel preparation using Bisacodyl combined with repeated water enemas until the appearance of clear return fluid (BE) on bowel preparation and to compare patient compliance in a randomized-investigator blinded trial."( Oral sodium phosphate compared with water enemas combined with bisacodyl as bowel preparation for elective colonoscopy.
Bohlbro, K; Qvist, N; Rasmussen, M, 2003
)
0.76
"Two liters of polyethylene glycol (PEG) solution administered with ascorbic acid (Asc) can provide efficacy similar to that of a 4-L PEG solution for colonoscopy preparation."( Comparable Efficacy of a 1-L PEG and Ascorbic Acid Solution Administered with Bisacodyl versus a 2-L PEG and Ascorbic Acid Solution for Colonoscopy Preparation: A Prospective, Randomized and Investigator-Blinded Trial.
Im, JP; Jung, HC; Kim, BG; Kim, JS; Kim, JW; Kim, SG; Kim, SH; Koh, SJ; Kwon, JE; Lee, JW; Lee, KL, 2016
)
0.66

Bioavailability

ExcerptReferenceRelevance
" The rate of absorption decreased from the colon to the duodenum (colon greater than ileum greater than jejunum greater than duodenum)."( Intestinal oxalate absorption. I. Absorption in vitro.
Caspary, WF, 1977
)
0.26
" The absorption rate was small, especially in the colon (0."( Appearance of 14C-polyethylene glycol 4000 in intestinal venous blood: influence of osmolarity and laxatives, effect on net water flux determination.
Görig, H; Winne, D, 1982
)
0.26
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

The bowel-cleansing effects and patient acceptability of split-dose P/MC were superior to day-before dosing with 2L PEG-3350 and bisacodyl tablets. 32-tablet sodium phosphate dosing regimen was easier to take and better tolerated, when compared to 2L polyethylene glycol plus bisac Cody tablets for bowel preparation.

ExcerptRelevanceReference
" The aim of the present investigation is therefore to study the absorption and the plasma level profile and to correlate plasma level profile and laxative effect after the administration of various dosage forms."( [Pharmacokinetics and laxative effect of bisacodyl following administration of various dosage forms].
Beschke, K; Roth, W, 1988
)
0.54
" Deacetylbisacodyl was more potent than the parent compound and was used to investigate dose-response relationships."( The influence of bisacodyl and deacetylbisacodyl on mucus secretion, mucus synthesis and electrolyte movements in the rat colon in vivo.
Farack, UM; Gruber, E; Loeschke, K, 1985
)
1.03
" Manufacturer guidelines should be consulted for proper dosing and administration."( Therapeutic modalities for mechanical cleansing of the colon.
Danziger, LH; Messick, CR, 1996
)
0.29
"The colon-cleansing efficacy of the new 32-tablet NaP dosing regimen in this study was found to be significantly better than the 2L PEG solution plus bisacodyl tablets regimen."( A randomized, multicenter study comparing the safety and efficacy of sodium phosphate tablets with 2L polyethylene glycol solution plus bisacodyl tablets for colon cleansing.
Carter, E; Cohen, LB; Forbes, WP; Johanson, JF; Lottes, SR; Popp, JW; Rose, M; Walker, K; Zhang, B, 2007
)
0.74
"The 32-tablet sodium phosphate dosing regimen was easier to take and better tolerated, when compared to 2L polyethylene glycol plus bisacodyl tablets for bowel preparation."( Clinical trial: sodium phosphate tablets are preferred and better tolerated by patients compared to polyethylene glycol solution plus bisacodyl tablets for bowel preparation.
Forbes, WP; Grandhi, N; Lichtenstein, GR; Lottes, SR; Schmalz, M; Walker, K; Zhang, B, 2007
)
0.75
" C(max) was attained approximately 5 h after dosing of Bisa and 9 h after dosing of SPS."( Absence of excretion of the active moiety of bisacodyl and sodium picosulfate into human breast milk: an open-label, parallel-group, multiple-dose study in healthy lactating women.
de Kruif, S; Friedrich, C; Gessner, U; Mandel, K; Richter, E; Trommeshauser, D; van Iersel, T, 2011
)
0.63
" Nonetheless, this could have implications in patients with pre-existing electrolyte abnormalities and the safety of dosing with more than two sachets."( Serial monitoring of the physiological effects of the standard Pico-Salax® regimen for colon cleansing in healthy volunteers.
Baranchuk, A; Hookey, LC; Rahman, A; Vanner, SJ, 2012
)
0.38
"To compare the frequency of excellent/good/fair/poor bowel cleansing with PM-only dosing of MiraLAX-Gatorade-bisacodyl versus 4-liter GoLytely."( MiraLAX-Gatorade bowel prep versus GoLytely before screening colonoscopy: an endoscopic database study in a community hospital.
Gunaratnam, N; Mohamud, SO; Schoenfeld, P; Shieh, FK,
)
0.34
" All patients used PM-only dosing of bowel purgative."( MiraLAX-Gatorade bowel prep versus GoLytely before screening colonoscopy: an endoscopic database study in a community hospital.
Gunaratnam, N; Mohamud, SO; Schoenfeld, P; Shieh, FK,
)
0.13
"This phase 3 study investigated the efficacy, safety, and tolerability of split-dose administration of P/MC versus day-before dosing of 2L PEG-3350 and two 5-mg bisacodyl tablets (SEE CLEAR I study)."( Split-dose administration of a dual-action, low-volume bowel cleanser for colonoscopy: the SEE CLEAR I study.
Alderfer, V; Bertiger, G; Hookey, LC; Joseph, RE; Katz, PO; Rex, DK; Vanner, S, 2013
)
0.59
"The bowel-cleansing effects and patient acceptability of split-dose P/MC were superior to day-before dosing with 2L PEG-3350 and bisacodyl tablets."( Split-dose administration of a dual-action, low-volume bowel cleanser for colonoscopy: the SEE CLEAR I study.
Alderfer, V; Bertiger, G; Hookey, LC; Joseph, RE; Katz, PO; Rex, DK; Vanner, S, 2013
)
0.59
" Regardless of preparation, split dosage was associated with better cleansing."( Colon Cleansing for Colonoscopy in Patients with Ulcerative Colitis: Efficacy and Acceptability of a 2-L PEG Plus Bisacodyl Versus 4-L PEG.
Ardizzone, S; de Nucci, G; Fontana, P; Hassan, C; Manes, G; Radaelli, F, 2015
)
0.63
" Low-volume polyethylene glycol (PEG) plus ascorbic acid (PEG-Asc) reduces the dosage of bowel preparation agent, but still presents discomfort to patients."( Combination of bisacodyl suppository and 1 L polyethylene glycol plus ascorbic acid is a non-inferior and comfortable regimen compared to 2 L polyethylene glycol plus ascorbic acid.
Chang, DK; Hong, SN; Kim, ER; Kim, K; Kim, SH; Kim, TJ; Kim, YH, 2020
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (86)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
acetylcholinesteraseHomo sapiens (human)Potency41.66790.002541.796015,848.9004AID1347395
RAR-related orphan receptor gammaMus musculus (house mouse)Potency1.67850.006038.004119,952.5996AID1159521
SMAD family member 2Homo sapiens (human)Potency11.55230.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency11.55230.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency21.57660.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency24.66130.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency9.42800.000221.22318,912.5098AID1259243; AID1259247; AID588516; AID743036; AID743042; AID743054; AID743063
thioredoxin glutathione reductaseSchistosoma mansoniPotency89.12510.100022.9075100.0000AID485364
signal transducer and activator of transcription 6, interleukin-4 inducedHomo sapiens (human)Potency0.39812.51199.410115.8489AID922; AID935
hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor)Homo sapiens (human)Potency0.64780.00137.762544.6684AID914; AID915
thyroid stimulating hormone receptorHomo sapiens (human)Potency1.88540.001318.074339.8107AID926; AID938
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency2.95680.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency15.23970.001022.650876.6163AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency60.75780.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency9.77170.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency6.95170.000214.376460.0339AID588533; AID720691
retinoid X nuclear receptor alphaHomo sapiens (human)Potency27.45160.000817.505159.3239AID1159527; AID1159531; AID588544; AID588546
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency59.62490.001530.607315,848.9004AID1224848; AID1224849; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency37.93020.375827.485161.6524AID588527; AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency46.98050.005428.02631,258.9301AID1346982; AID720659
estrogen nuclear receptor alphaHomo sapiens (human)Potency7.46730.000229.305416,493.5996AID1259244; AID1259248; AID588513; AID588514; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091
GVesicular stomatitis virusPotency17.37680.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency15.48710.00108.379861.1304AID1645840
glucocerebrosidaseHomo sapiens (human)Potency39.81070.01268.156944.6684AID2101
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency16.98580.001024.504861.6448AID743212; AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency44.66840.001019.414170.9645AID588537
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency28.49460.023723.228263.5986AID743222
IDH1Homo sapiens (human)Potency0.58050.005210.865235.4813AID686970
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency3.01500.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency19.76050.001628.015177.1139AID1224895; AID1259385; AID1259395
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency2.205219.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency0.56090.057821.109761.2679AID1159526; AID1159528
cytochrome P450 2C9 precursorHomo sapiens (human)Potency15.84890.00636.904339.8107AID883
thyroid hormone receptor beta isoform aHomo sapiens (human)Potency0.00630.010039.53711,122.0200AID588545
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency0.05800.00419.984825.9290AID504444
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency15.84890.01789.637444.6684AID588834
heat shock protein beta-1Homo sapiens (human)Potency21.74400.042027.378961.6448AID743210
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency45.16950.000627.21521,122.0200AID651741; AID743202; AID743219
gemininHomo sapiens (human)Potency3.66260.004611.374133.4983AID624296
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency40.53340.005612.367736.1254AID624032
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency11.04060.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency0.39470.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency8.51260.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency0.49900.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency17.37680.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency17.37680.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency0.62990.002319.595674.0614AID651631; AID720552
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency0.49900.001551.739315,848.9004AID1259244
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency15.84890.00638.235039.8107AID883
Nuclear receptor ROR-gammaHomo sapiens (human)Potency0.07500.026622.448266.8242AID651802
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency1.41250.009610.525035.4813AID1479145
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency17.37680.01238.964839.8107AID1645842
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency11.04061.000012.224831.6228AID885
cytochrome P450 2C9, partialHomo sapiens (human)Potency17.37680.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Mcl-1Homo sapiens (human)IC50 (µMol)54.00000.40007.134454.0000AID1418
G-protein coupled receptor 35 isoform aHomo sapiens (human)IC50 (µMol)32.00000.16002.30197.6600AID2058
G-protein coupled receptor 55Homo sapiens (human)IC50 (µMol)0.90840.12502.58609.7907AID2013
ATP-binding cassette sub-family C member 3Homo sapiens (human)IC50 (µMol)133.00000.63154.45319.3000AID1473740
Multidrug resistance-associated protein 4Homo sapiens (human)IC50 (µMol)133.00000.20005.677410.0000AID1473741
Bile salt export pumpHomo sapiens (human)IC50 (µMol)94.68000.11007.190310.0000AID1449628; AID1473738
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00052.773925.1700AID1418
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00052.891925.1700AID1418
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00052.747825.1700AID1418
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00052.780225.1700AID1418
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)IC50 (µMol)54.00000.00053.314249.5000AID1418
Cytochrome P450 2C9 Homo sapiens (human)IC50 (µMol)10.00000.00002.800510.0000AID625248
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)2.43700.00001.201110.0000AID625162
Kappa-type opioid receptorHomo sapiens (human)Ki0.97500.00000.362410.0000AID625162
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)2.20800.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki1.75500.00021.11158.0280AID625256
Canalicular multispecific organic anion transporter 1Homo sapiens (human)IC50 (µMol)133.00002.41006.343310.0000AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aryl hydrocarbon receptorHomo sapiens (human)EC50 (µMol)1,000.00000.00151.976910.0000AID1706081
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (293)

Processvia Protein(s)Taxonomy
xenobiotic metabolic processATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
bile acid and bile salt transportATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transportATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
leukotriene transportATP-binding cassette sub-family C member 3Homo sapiens (human)
monoatomic anion transmembrane transportATP-binding cassette sub-family C member 3Homo sapiens (human)
transport across blood-brain barrierATP-binding cassette sub-family C member 3Homo sapiens (human)
prostaglandin secretionMultidrug resistance-associated protein 4Homo sapiens (human)
cilium assemblyMultidrug resistance-associated protein 4Homo sapiens (human)
platelet degranulationMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic metabolic processMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
bile acid and bile salt transportMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transportMultidrug resistance-associated protein 4Homo sapiens (human)
urate transportMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
cAMP transportMultidrug resistance-associated protein 4Homo sapiens (human)
leukotriene transportMultidrug resistance-associated protein 4Homo sapiens (human)
monoatomic anion transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
export across plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
transport across blood-brain barrierMultidrug resistance-associated protein 4Homo sapiens (human)
guanine nucleotide transmembrane transportMultidrug resistance-associated protein 4Homo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C9 Homo sapiens (human)
steroid metabolic processCytochrome P450 2C9 Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2C9 Homo sapiens (human)
estrogen metabolic processCytochrome P450 2C9 Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C9 Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
urea metabolic processCytochrome P450 2C9 Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 2C9 Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C9 Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
amide metabolic processCytochrome P450 2C9 Homo sapiens (human)
icosanoid biosynthetic processCytochrome P450 2C9 Homo sapiens (human)
oxidative demethylationCytochrome P450 2C9 Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C9 Homo sapiens (human)
blood vessel developmentAryl hydrocarbon receptorHomo sapiens (human)
regulation of adaptive immune responseAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of T cell mediated immune response to tumor cellAryl hydrocarbon receptorHomo sapiens (human)
regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
regulation of transcription by RNA polymerase IIAryl hydrocarbon receptorHomo sapiens (human)
xenobiotic metabolic processAryl hydrocarbon receptorHomo sapiens (human)
apoptotic processAryl hydrocarbon receptorHomo sapiens (human)
response to xenobiotic stimulusAryl hydrocarbon receptorHomo sapiens (human)
response to toxic substanceAryl hydrocarbon receptorHomo sapiens (human)
regulation of gene expressionAryl hydrocarbon receptorHomo sapiens (human)
cAMP-mediated signalingAryl hydrocarbon receptorHomo sapiens (human)
intracellular receptor signaling pathwayAryl hydrocarbon receptorHomo sapiens (human)
regulation of B cell proliferationAryl hydrocarbon receptorHomo sapiens (human)
circadian regulation of gene expressionAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionAryl hydrocarbon receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIAryl hydrocarbon receptorHomo sapiens (human)
negative regulation of inflammatory responseAryl hydrocarbon receptorHomo sapiens (human)
cellular response to molecule of bacterial originAryl hydrocarbon receptorHomo sapiens (human)
cellular response to cAMPAryl hydrocarbon receptorHomo sapiens (human)
cellular response to forskolinAryl hydrocarbon receptorHomo sapiens (human)
cellular response to 2,3,7,8-tetrachlorodibenzodioxineAryl hydrocarbon receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
xenobiotic metabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
negative regulation of gene expressionCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bile acid and bile salt transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
heme catabolic processCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic export from cellCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transepithelial transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
leukotriene transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
monoatomic anion transmembrane transportCanalicular multispecific organic anion transporter 1Homo sapiens (human)
transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transport across blood-brain barrierCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (108)

Processvia Protein(s)Taxonomy
ATP bindingATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
glucuronoside transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type bile acid transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATP hydrolysis activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
icosanoid transmembrane transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
ABC-type transporter activityATP-binding cassette sub-family C member 3Homo sapiens (human)
guanine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ATP bindingMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type xenobiotic transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
prostaglandin transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
urate transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
purine nucleotide transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type bile acid transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
efflux transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATP hydrolysis activityMultidrug resistance-associated protein 4Homo sapiens (human)
glutathione transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
xenobiotic transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
ABC-type transporter activityMultidrug resistance-associated protein 4Homo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
iron ion bindingCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 14,15-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
arachidonic acid 11,12-epoxygenase activityCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
caffeine oxidase activityCytochrome P450 2C9 Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C9 Homo sapiens (human)
aromatase activityCytochrome P450 2C9 Homo sapiens (human)
heme bindingCytochrome P450 2C9 Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C9 Homo sapiens (human)
nuclear receptor activityAryl hydrocarbon receptorHomo sapiens (human)
transcription cis-regulatory region bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificAryl hydrocarbon receptorHomo sapiens (human)
cis-regulatory region sequence-specific DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
TFIID-class transcription factor complex bindingAryl hydrocarbon receptorHomo sapiens (human)
transcription coactivator bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
DNA-binding transcription factor activityAryl hydrocarbon receptorHomo sapiens (human)
nuclear receptor activityAryl hydrocarbon receptorHomo sapiens (human)
protein bindingAryl hydrocarbon receptorHomo sapiens (human)
TBP-class protein bindingAryl hydrocarbon receptorHomo sapiens (human)
protein homodimerization activityAryl hydrocarbon receptorHomo sapiens (human)
protein heterodimerization activityAryl hydrocarbon receptorHomo sapiens (human)
Hsp90 protein bindingAryl hydrocarbon receptorHomo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingAryl hydrocarbon receptorHomo sapiens (human)
E-box bindingAryl hydrocarbon receptorHomo sapiens (human)
sequence-specific double-stranded DNA bindingAryl hydrocarbon receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP bindingCanalicular multispecific organic anion transporter 1Homo sapiens (human)
organic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type xenobiotic transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
bilirubin transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATP hydrolysis activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
xenobiotic transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
ABC-type transporter activityCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (66)

Processvia Protein(s)Taxonomy
plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basal plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
basolateral plasma membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
membraneATP-binding cassette sub-family C member 3Homo sapiens (human)
nucleolusMultidrug resistance-associated protein 4Homo sapiens (human)
Golgi apparatusMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
platelet dense granule membraneMultidrug resistance-associated protein 4Homo sapiens (human)
external side of apical plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
plasma membraneMultidrug resistance-associated protein 4Homo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C9 Homo sapiens (human)
plasma membraneCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
cytoplasmCytochrome P450 2C9 Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C9 Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
nucleusAryl hydrocarbon receptorHomo sapiens (human)
nuclear aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
nucleusAryl hydrocarbon receptorHomo sapiens (human)
nucleoplasmAryl hydrocarbon receptorHomo sapiens (human)
cytoplasmAryl hydrocarbon receptorHomo sapiens (human)
cytosolAryl hydrocarbon receptorHomo sapiens (human)
chromatinAryl hydrocarbon receptorHomo sapiens (human)
transcription regulator complexAryl hydrocarbon receptorHomo sapiens (human)
protein-containing complexAryl hydrocarbon receptorHomo sapiens (human)
cytosolic aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
aryl hydrocarbon receptor complexAryl hydrocarbon receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
cell surfaceCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
intercellular canaliculusCanalicular multispecific organic anion transporter 1Homo sapiens (human)
apical plasma membraneCanalicular multispecific organic anion transporter 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (93)

Assay IDTitleYearJournalArticle
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1706079Agonist activity at AhR in human HepG2 cells co-transfected with pSELECT-zeo-Lucia and CYP1A1 assessed as induction of receptor transactivation at 10 uM incubated for 24 hrs by luciferase reporter gene assay relative to control2020European journal of medicinal chemistry, Dec-01, Volume: 207Targeting the aryl hydrocarbon receptor with a novel set of triarylmethanes.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID625294Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in O'Brien data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1706084Antagonist activity at AhR in human HepG2 cells co-transfected with pSELECT-zeo-Lucia and CYP1A1 assessed as inhibition of FICZ-induced receptor transactivation at 10 uM incubated for 24 hrs by luciferase reporter gene assay relative to control2020European journal of medicinal chemistry, Dec-01, Volume: 207Targeting the aryl hydrocarbon receptor with a novel set of triarylmethanes.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1706081Agonist activity at AhR in human HepG2 cells co-transfected with pSELECT-zeo-Lucia and CYP1A1 assessed as induction of receptor transactivation incubated for 24 hrs by luciferase reporter gene assay2020European journal of medicinal chemistry, Dec-01, Volume: 207Targeting the aryl hydrocarbon receptor with a novel set of triarylmethanes.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (448)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990150 (33.48)18.7374
1990's65 (14.51)18.2507
2000's75 (16.74)29.6817
2010's117 (26.12)24.3611
2020's41 (9.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 78.41

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index78.41 (24.57)
Research Supply Index6.44 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index196.78 (26.88)
Search Engine Supply Index2.82 (0.95)

This Compound (78.41)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials142 (29.40%)5.53%
Reviews26 (5.38%)6.00%
Case Studies28 (5.80%)4.05%
Observational3 (0.62%)0.25%
Other284 (58.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (65)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
[NCT02119000]Phase 482 participants (Actual)Interventional2015-08-31Terminated(stopped due to Difficulty in recruitment)
Simultaneous Combination of Bisacodyl Suppository Agent and 1L Polyethylene Glycol Plus Ascorbic Acid is Not Inferior and Comfortable Regimen Compared With 2L Polyethylene Glycol Plus Ascorbic Acid: A Randomized Controlled Study [NCT03849196]168 participants (Actual)Interventional2017-07-31Completed
Comparison of Single-dose (Morning) Low-volume Polyethylene Glycol Plus Bisacodyl Versus Split-dose Polyethylene Glycol for Bowel Preparation Efficacy in Patient Receiving Morning Colonoscopy [NCT03248726]122 participants (Actual)Interventional2017-07-14Completed
"A Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety and Tolerability of Split-Dose PicoPrep™ for Oral Administration Versus HalfLytely® for Colon Cleansing in Preparation for Colonoscopy" [NCT01073930]Phase 3608 participants (Actual)Interventional2010-05-31Completed
Bisacodyl Use in the Post-operative Care of Obstetrical/Gynecological (OB/GYN) Patients [NCT01011426]Phase 2285 participants (Anticipated)Interventional2009-04-30Completed
A Randomized, Controlled, Parallel Group, Assessor-Blinded Study To Compare The Efficacy, Tolerability, And Safety Of Oral Sodium Picosulfate (PicoPrep®) Versus Oral Mannitol and Bisacodyl, For Colon Cleansing In Colonoscopy Preparation Of Adult Outpatien [NCT02386449]Phase 4184 participants (Actual)Interventional2015-02-28Completed
Interventions to Decrease the Impact of Post-Operative Ileus After Liver Transplant or Resection Surgery [NCT01156129]Phase 1111 participants (Actual)Interventional2010-09-01Completed
Evaluating the Effectiveness of a Same-day, Reduced Volume Polyethylene Glycol + Electrolyte Solution (PEG-ELS) Bowel Preparation for Afternoon Colonoscopies [NCT01044394]Phase 20 participants (Actual)Interventional2010-01-31Withdrawn(stopped due to A phase III RCT was published showing this approach is effective)
Investigation of the Pharmacokinetics of 10 mg Bisacodyl (Coated Tablets) or 10 mg Sodium Picosulfate (Drops) Administered Orally in Healthy Lactating Females [NCT02211911]Phase 116 participants (Actual)Interventional2008-02-29Completed
Personalized Colonoscopy Preparation for Patients With Risk Factors for Inadequate Preparation: A Randomized Control Trial [NCT04033250]600 participants (Anticipated)Interventional2019-09-30Recruiting
Screening for Colorectal Cancer in Average and High Risk Iraqi Population: A Pilot Study [NCT04017845]Early Phase 1537 participants (Actual)Interventional2015-04-01Completed
MoviPrep® Versus HalfLytely® for Colon Cleansing: An Investigator-blinded, Randomized Trial. [NCT00779649]Phase 4220 participants (Anticipated)Interventional2008-09-30Completed
Unrestricted Diet vs 1-day Low Residue Diet for Screening Colonoscopy [NCT05032794]553 participants (Actual)Interventional2021-10-13Completed
A Prospective, Randomized, Evaluator Blind, Active-Controlled, Parallel Study of the Efficacy and Safety of Quiklean® and Klean-Prep With Dulcolax® for the Bowel Preparation Prior to Colonoscopy [NCT03992365]Phase 3472 participants (Actual)Interventional2019-06-10Completed
A Phase IV, Crossover, Randomized, Double Blind and Placebo-controlled Clinical Trial to Evaluate the Mode of Action of Multiple Doses of Bisacodyl in Subjects With Occasional Constipation [NCT04129788]Phase 410 participants (Anticipated)Interventional2020-11-04Recruiting
Optimal Bowel Preparation Regimen for Patients With With a History of Colorectal Resection Before Colonoscopy [NCT02761317]Phase 4300 participants (Anticipated)Interventional2016-05-31Recruiting
Multidisciplinary Approach Versus Conventional Approach in Colonic Preparation of Hospitalized Patients. A Randomized Controlled Trial [NCT01853709]Phase 4162 participants (Anticipated)Interventional2013-05-31Not yet recruiting
Low-dose Laxative Improves Performance and Feasibility of Computed Tomography Colonography (CTC). Comparison vs Laxative Free CTC. [NCT02040285]Phase 452 participants (Actual)Interventional2012-02-29Completed
A Randomised, Double-blind, Placebo-controlled, Parallel Group Study to Assess the Efficacy and Safety of 4 Weeks Treatment With Bisacodyl (Dulcolax) Tablets 10mg Administered Orally, Once Daily, in Patients With Functional Constipation. [NCT00526097]Phase 3368 participants (Actual)Interventional2007-09-30Completed
Preoperative Bowel Preparation Versus no Preparation Before Spinal Surgery: a Randomised Clinical Trial [NCT01879605]Phase 445 participants (Actual)Interventional2007-12-31Completed
Phase 4 Study of Comparison of 2-Liter Mixed Preparation With Bisacodyl Plus Polyethylene Glycol and 4-Liter Polyethylene Glycol for Colon Cleansing in Patients With Prior History of Colorectal Resection. A Prospective Randomized Controlled Trial. [NCT01887158]Phase 4116 participants (Actual)Interventional2013-07-31Completed
Understanding Defecation Patterns Using a Novel Device (Fecobionics) to Improve Treatment of Constipation [NCT04903470]130 participants (Anticipated)Interventional2021-06-15Recruiting
Bowel Cleansing for Colonoscopy: Comparison Between a Same Day Low-Volume Preparation and a Conventional 4L Split One. A Randomized, Observer-blind, Parallel Group, Comparative Study. [NCT01685853]Phase 3164 participants (Actual)Interventional2011-04-30Completed
Phase III of the AB Prep Safety and Efficacy in Colon Cleansing [NCT00817934]400 participants (Anticipated)Observational2009-01-31Active, not recruiting
RELISTOR's Effects on Opioid-Induced Constipation in Postoperative 1-2 Level Anterior Lumbar Interbody Fusion Patients: A Case-Control Study [NCT04930237]0 participants (Actual)Observational2021-07-01Withdrawn(stopped due to PI request to close study)
A Phase 1, Single-center, Open-label Study to Evaluate the Pharmacokinetics, Metabolism, and Excretion of [14C] BMS-986166 in Healthy Male Participants [NCT05409157]Phase 17 participants (Actual)Interventional2022-06-17Completed
"A Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety and Tolerability of Day Before PicoPrep™ for Oral Administration Versus HalfLytely® for Colon Cleansing in Preparation for Colonoscopy" [NCT01073943]Phase 3603 participants (Actual)Interventional2010-05-31Completed
A Randomized Prospective Trial Comparing Pico-Salax (Magnesium Citrate) Plus Bisacodyl Versus Split Dose Polyethylene Glycol-Based Lavage In Preparation Of Patients For Colonoscopy [NCT01415687]Phase 3171 participants (Actual)Interventional2011-05-31Completed
High-volume Polyethylene Glycol Solution (PEG) Versus Low-volume PEG Plus Stimulant Laxative Versus Sennosides for Colon Cleansing Before Colonoscopy: a Randomized, Single Blinded Study [NCT01531140]Phase 4240 participants (Actual)Interventional2010-11-30Completed
2L Oral Bi-PegLyte Versus 2L Oral MoviPrep Regimen for Outpatient Colonic Preparation: A Randomized, Non-Inferiority Open Trial [NCT01865916]Phase 4309 participants (Actual)Interventional2013-04-30Completed
An Open-label, Randomised, Crossover, Reader Blinded, Study to Compare the Effect of Polyethylene Glycol 3350, Bisacodyl and Prucalopride on Colonic Motility Assessed With Intraluminal Colonic Manometry in Healthy Subjects [NCT03279341]Phase 410 participants (Actual)Interventional2012-12-03Completed
Randomized Clinical Trial of Bisacodyl Versus Placebo on Postoperative Bowel Motility in Elective Colorectal Surgery [NCT00509327]Phase 4200 participants (Actual)Interventional2004-11-30Completed
A Phase IV, Crossover, Randomized, Double Blind and Placebo-controlled Clinical Trial to Evaluate the Mode of Action of a Single Dose of Bisacodyl in Subjects With Occasional Constipation [NCT04132661]Phase 410 participants (Anticipated)Interventional2020-09-25Recruiting
Retrospective, Uncontrolled Multcentric Cohort Study on the Therapy of Chronic Megalon (CoMeC) [NCT04340856]67 participants (Actual)Observational2020-05-07Completed
Lactulose vs. Polyethylene Glycol as Bowel Preparation for Colonoscopy in Adults [NCT05726344]150 participants (Actual)Interventional2023-02-10Completed
A Randomized, Blinded Trial Comparing Miralax With Amitiza Pretreatment Versus Miralax With Dulcolax Pretreatment Versus Miralax Alone Without Pretreatment Versus Golytely for Bowel Cleansing Prior to Colonoscopy [NCT00953017]Phase 4425 participants (Actual)Interventional2009-07-31Completed
Lubiprostone for the Treatment of Functional Constipation in the Under 18 Years Patients: A Randomized, Controlled Trial. [NCT05144295]Phase 3274 participants (Actual)Interventional2022-01-01Completed
Evaluation of Reduced-volume PEG Bowel Preparation Administered the Same Day of Colonoscopy [NCT01533090]162 participants (Actual)Interventional2010-04-30Completed
A Randomized, 12-Week, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of Plecanatide (3.0 and 6.0 mg) in Patients With Chronic Idiopathic Constipation (The CIC3 Study) [NCT01982240]Phase 31,394 participants (Actual)Interventional2013-11-30Completed
Treating Anorectal Dysfunction Associated With Multiple Sclerosis [NCT02609607]Phase 211 participants (Actual)Interventional2016-06-30Terminated(stopped due to Poor enrollment; funding ending Dec 31, 2018.)
A Randomized Controlled Trial Comparing Picosalax and Oral Sodium Phosphate for Colon Cleansing Prior to Colonoscopy [NCT00410215]Phase 4315 participants (Actual)Interventional2006-02-28Completed
Comparative Efficacy and Tolerability of Bisacodyl Sugar Coated Tablets, Simeticone Chewing Tablets and the Combination of Both in the Treatment of Constipation and Bloatedness: an Open, Randomised, Parallel Group Trial [NCT02211976]Phase 330 participants (Actual)Interventional2003-10-31Completed
An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects [NCT00278967]Phase 4450 participants Interventional2006-02-28Completed
A Safety and Efficacy Evaluation of 3 Bowel Preparations in the Pediatric Population [NCT00425594]Phase 4150 participants Interventional2007-01-31Completed
Low Volume Bowel Preparation for Colonoscopy: a Comparison Between PEG-CS Plus Bisacodyl Versus PEG-ASC [NCT01509131]Phase 4408 participants (Actual)Interventional2010-03-31Completed
The Outcome of a Second Preparation for Colonoscopy After Preparation Failure in the First Procedure: a Prospective Randomized Controlled Study [NCT01510977]Phase 4150 participants (Actual)Interventional2011-11-30Terminated
A Randomized Control Trial Comparing 4L PEGlyte to Regular Dose Pico-Salax and Split Dose Pico-Salax for Colonoscopy Bowel Preparation in Hospitalized Patients [NCT01627171]Phase 4126 participants (Anticipated)Interventional2012-09-30Recruiting
Improving Bowel Preparation for the Colon Capsule: Picosalax and Prucalopride vs. PEG and Prucalopride [NCT01655095]Phase 320 participants (Actual)Interventional2012-07-31Completed
Comparison Between 2L Coolprep® and Combination of 1L Coolprep® and Bisacodyl as Bowel Preparation for Colonoscopy [NCT01745835]Phase 3196 participants (Actual)Interventional2013-01-30Completed
F38-27: An Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects [NCT00857272]Phase 4308 participants (Actual)Interventional2009-02-28Completed
The Use of Methylnaltrexone to Reduce Post-operative Opioid-induced Constipation in the Pediatric Spinal Fusion Patient [NCT01773096]Phase 460 participants (Anticipated)Interventional2013-05-31Completed
COVGIC20482: A Multicenter, Consecutive, Randomized Study to Optimize the Bowel Preparation Regimen for the PillCam COLON 2 Capsule Endoscopy Procedure [NCT02481219]122 participants (Actual)Interventional2015-05-31Completed
An Interdisciplinary Approach to the Treatment of Encopresis in Children With Autism Spectrum Disorders [NCT02383758]22 participants (Actual)Interventional2015-02-01Completed
Effect of Octreotide on the Colonic Motility in Pediatric Patients [NCT01917773]Phase 413 participants (Actual)Interventional2013-08-31Completed
Comparison of a Split Dose Bowel Preparation With 2-L Polyethylene Glycol Plus Ascorbic Acid and 1-L Polyethylene Glycol Plus Ascorbic Acid and Bisacodyl Prior to Colonoscopy [NCT02980562]Phase 3200 participants (Actual)Interventional2015-05-31Completed
Gatorade/Miralax With or Without Bisacodyl vs NuLytely for Colonoscopy Preparation [NCT01063049]Phase 4600 participants (Actual)Interventional2010-02-28Completed
2L Golytely and Oral Bisacodyl 15 mg Versus 4L Golytely Regimen for Inpatient Colonoscopy Bowel Preparation: A Randomized, Non-Inferiority Open Trial [NCT01452737]0 participants (Actual)Interventional2011-11-30Withdrawn
Efficacy and Tolerability of Various Bowel Preparations in Diabetic Patients: A Randomized Controlled Trial [NCT01533688]212 participants (Actual)Interventional2011-10-31Completed
A Multi-centre Endoscopist Blinded Randomized Clinical Trial to Compare Two Bowel Preparations After a Colonoscopy With Inadequate Bowel Preparation [NCT02976805]Phase 3196 participants (Actual)Interventional2017-02-13Completed
Impact of Naloxegol on Prevention of Lower GI Tract Paralysis in Critically Ill Adults Initiated on Scheduled Intravenous Opioid Therapy: A Randomized, Double-Blind, Placebo-Controlled, Phase II, Single-Center, Proof of Concept Study [NCT02977286]Phase 412 participants (Actual)Interventional2017-01-01Terminated(stopped due to Poor enrollment)
Comparison Between Asymmetric (Low Dose In The Morning) And Standard Split-Dose Regimen Of Polyethylene Glycol Plus Bisacodyl For Bowel Preparation For Screening And Surveillance Colonoscopy: A Randomized Non-Inferiority Clinical Trial. [NCT03146052]81 participants (Actual)Interventional2017-03-27Completed
Efficacy of Magnesium Citrate Capsules in Colonoscopy Preparation: A Randomized, Investigator-blinded Non-inferiority Trial Using Polyethylene Glycol as the Active Control. [NCT03247595]62 participants (Actual)Interventional2017-09-26Completed
Reclassifying Constipation Using Magnetic Resonance Imaging Combined With High Resolution Manometry: A Validation Study And Double-Blind Crossover Trial [NCT03226145]120 participants (Anticipated)Interventional2017-07-20Recruiting
Tailored Bowel Preparation According to Bristol Stool Form Scale: a Prospective, Randomized, Controlled, Investigator-blinded, Multicenter Study [NCT02415569]Phase 4700 participants (Actual)Interventional2015-01-31Completed
Evaluation of Oral Tolerance MiraLAX Solution Concentrate in Subjects With Chronic Constipation [NCT01885104]Phase 265 participants (Actual)Interventional2013-04-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 4
NCT00526097 (86) [back to overview]Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 4 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 1 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 2 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 3 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 4 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Respect to the Final Global Assessment of Efficacy by the Investigator
NCT00526097 (86) [back to overview]Number of Participants With Respect to the Final Global Assessment of Efficacy by the Patient
NCT00526097 (86) [back to overview]Number of Participants With Respect to the Final Global Assessment of Tolerability by the Investigator
NCT00526097 (86) [back to overview]Change From Baseline for Chloride (Normalized Value)
NCT00526097 (86) [back to overview]Change From Baseline for Potassium (Normalized Value)
NCT00526097 (86) [back to overview]Change From Baseline for Sodium (Normalized Value)
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 1
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 2
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 3
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 4
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 1
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 2
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 3
NCT00526097 (86) [back to overview]Change From Baseline in the SF-36 Dimension 'General Health'
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 1
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 2
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 3
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 4
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 1
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 2
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 3
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 4
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 1
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 2
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 3
NCT00526097 (86) [back to overview]Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 4
NCT00526097 (86) [back to overview]Change From Baseline in the PAC-QoL Overall Score
NCT00526097 (86) [back to overview]Change From Baseline in the PAC-QoL Subscale 'Physical Discomfort'
NCT00526097 (86) [back to overview]Change From Baseline in the PAC-QoL Subscale 'Psychosocial Discomfort'
NCT00526097 (86) [back to overview]Change From Baseline in the PAC-QoL Subscale 'Satisfaction'
NCT00526097 (86) [back to overview]Change From Baseline in the PAC-QoL Subscale 'Worries and Concerns'
NCT00526097 (86) [back to overview]Change From Baseline in the SF-36 Dimension 'Bodily Pain'
NCT00526097 (86) [back to overview]Number of Participants With Respect to the Final Global Assessment of Tolerability by the Patient
NCT00526097 (86) [back to overview]Change From Baseline in the SF-36 Dimension 'Mental Health'
NCT00526097 (86) [back to overview]Change From Baseline in the SF-36 Dimension 'Physical Functioning'
NCT00526097 (86) [back to overview]Change From Baseline in the SF-36 Dimension 'Role Limitation Due to Emotional Problems'
NCT00526097 (86) [back to overview]Change From Baseline in the SF-36 Dimension 'Role Limitation Due to Physical Problems'
NCT00526097 (86) [back to overview]Change From Baseline in the SF-36 Dimension 'Social Functioning'
NCT00526097 (86) [back to overview]Change From Baseline in the SF-36 Dimension 'Vitality'
NCT00526097 (86) [back to overview]Change From Baseline in the SF-36 Mental Component Scale (MCS)
NCT00526097 (86) [back to overview]Change From Baseline in the SF-36 Physical Component Scale (PCS)
NCT00526097 (86) [back to overview]Mean Number of Complete Spontaneous Bowel Movements (CSBMs) Per Week Over the 4 Weeks Treatment Period
NCT00526097 (86) [back to overview]Mean Number of SBMs Per Week Over the 4 Weeks Treatment Period
NCT00526097 (86) [back to overview]Number of CSBMs at Week 1
NCT00526097 (86) [back to overview]Number of CSBMs at Week 2
NCT00526097 (86) [back to overview]Number of CSBMs at Week 3
NCT00526097 (86) [back to overview]Number of CSBMs at Week 4
NCT00526097 (86) [back to overview]Number of Participants Using Rescue Medication at Week 1 in the Treatment Period
NCT00526097 (86) [back to overview]Number of Participants Using Rescue Medication at Week 2 in the Treatment Period
NCT00526097 (86) [back to overview]Number of Participants Using Rescue Medication at Week 3 in the Treatment Period
NCT00526097 (86) [back to overview]Number of Participants Using Rescue Medication at Week 4 in the Treatment Period
NCT00526097 (86) [back to overview]Number of Participants Using Rescue Medication Over the 4 Weeks Treatment Period
NCT00526097 (86) [back to overview]Number of Participants With a Mean of at Least 1 CSBM a Day Over the 4 Weeks Treatment Period
NCT00526097 (86) [back to overview]Number of Participants With a Mean of at Least 3 CSBMs a Week Over the 4 Weeks Treatment Period
NCT00526097 (86) [back to overview]Number of Participants With an Increase of at Least 1 CSBM at Week 1 Compared to Baseline
NCT00526097 (86) [back to overview]Number of Participants With an Increase of at Least 1 CSBM at Week 2 Compared to Baseline
NCT00526097 (86) [back to overview]Number of Participants With an Increase of at Least 1 CSBM at Week 3 Compared to Baseline
NCT00526097 (86) [back to overview]Number of Participants With an Increase of at Least 1 CSBM at Week 4 Compared to Baseline
NCT00526097 (86) [back to overview]Number of Participants With an Increase of at Least 1 in the Mean Number of CSBMs Per Week Over the 4 Weeks Treatment Period Compared to Baseline
NCT00526097 (86) [back to overview]Number of Premature Withdrawals at Week 1 in the Treatment Period
NCT00526097 (86) [back to overview]Number of Premature Withdrawals at Week 2 in the Treatment Period
NCT00526097 (86) [back to overview]Number of Premature Withdrawals at Week 3 in the Treatment Period
NCT00526097 (86) [back to overview]Number of Premature Withdrawals at Week 4 in the Treatment Period
NCT00526097 (86) [back to overview]Number of Premature Withdrawals Over the 4 Weeks Treatment Period
NCT00526097 (86) [back to overview]Number of SBMs at Week 1
NCT00526097 (86) [back to overview]Number of SBMs at Week 2
NCT00526097 (86) [back to overview]Number of SBMs at Week 3
NCT00526097 (86) [back to overview]Number of SBMs at Week 4
NCT00526097 (86) [back to overview]Time to the First SBM Following the First Dose of Study Medication (SM)
NCT00526097 (86) [back to overview]Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 1 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 2 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 3 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 4 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 1 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 2 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 3 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 4 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 1 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 2 in the Treatment Period in Comparison to Baseline
NCT00526097 (86) [back to overview]Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 3 in the Treatment Period in Comparison to Baseline
NCT00857272 (1) [back to overview]Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale
NCT00953017 (4) [back to overview]The Cleanliness of the Prep as Measured by the Ottawa Scale
NCT00953017 (4) [back to overview]Procedure Time
NCT00953017 (4) [back to overview]Polyps Detected
NCT00953017 (4) [back to overview]Patient Satisfaction With the Prep Measured by 5 Point Likert Scale
NCT01063049 (2) [back to overview]The Quality of the Colon Preparation Will be Graded Using the Boston Bowel Preparation Scale
NCT01063049 (2) [back to overview]The Ottawa Scale for Colonoscopy Preparation Will be Reported and Compared Among the 3 Groups to Allow for Comparisons to Some of the Older Literature
NCT01073930 (9) [back to overview]Percentage of Participants Classified as Successes (Excellent, Good and Fair Ratings) According to the Ottawa Scale As Assessed by a Blinded Gastroenterologist
NCT01073930 (9) [back to overview]Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: How Easy or Difficult Was It To Consume the Study Drug?
NCT01073930 (9) [back to overview]Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Please Describe Your Overall Experience With the Study Preparation
NCT01073930 (9) [back to overview]Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: The Taste of This Study Preparation Was
NCT01073930 (9) [back to overview]Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Were You Able to Consume the Entire Prep As Instructed?
NCT01073930 (9) [back to overview]Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Would You Ask Your Doctor for This Preparation Again if You Need Another Colonoscopy in the Future?
NCT01073930 (9) [back to overview]Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Would You Refuse the Same Preparation Again if it Were to be Prescribed to You in the Future?
NCT01073930 (9) [back to overview]Percentage of Participants Classified as Successes (Excellent and Good Ratings) According to the Aronchick Scale As Assessed by a Blinded Gastroenterologist
NCT01073930 (9) [back to overview]Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT01073943 (10) [back to overview]Percentage of Participants Classified as Successes (Excellent and Good Ratings) According to the Aronchick Scale As Assessed by a Blinded Gastroenterologist
NCT01073943 (10) [back to overview]Percentage of Participants Classified as Successes (Excellent, Good and Fair Ratings) For Ascending Colon Cleansing According to the Ottawa Scale As Assessed by a Blinded Gastroenterologist
NCT01073943 (10) [back to overview]Participants With Treatment-Emergent Adverse Events (TEAEs)
NCT01073943 (10) [back to overview]Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Would You Ask Your Doctor for This Preparation Again if You Need Another Colonoscopy in the Future?
NCT01073943 (10) [back to overview]Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Were You Able to Consume the Entire Prep As Instructed?
NCT01073943 (10) [back to overview]Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: The Taste of This Study Preparation Was
NCT01073943 (10) [back to overview]Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Please Describe Your Overall Experience With the Study Preparation
NCT01073943 (10) [back to overview]Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: How Easy or Difficult Was It To Consume the Study Drug?
NCT01073943 (10) [back to overview]Percentage of Participants Classified as Successes (Excellent, Good and Fair Ratings) For Colon Cleansing According to the Ottawa Scale As Assessed by a Blinded Gastroenterologist
NCT01073943 (10) [back to overview]Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Would You Refuse the Same Preparation Again if it Were to be Prescribed to You in the Future?
NCT01533688 (2) [back to overview]Measure of Patients Who Develop (Tolerance)Side Effects of Taking Bowel Preparations.
NCT01533688 (2) [back to overview]Measure the % of Participants With Effective (How Well the Colon is Cleansed Using the Validated Boston Bowel Preparation Scale) for Various Bowel Preparations for Colonoscopy.
NCT01885104 (2) [back to overview]Number of Participants With Inflammation of the Esophageal Mucosa
NCT01885104 (2) [back to overview]Number of Participants With Inflammation of the Oral Mucosa
NCT01917773 (1) [back to overview]Compared Colonic Motility Index From Fasting to Post Octreotide Infusion
NCT01982240 (5) [back to overview]Number of Durable Overall CSBM Responders , Mean Replacement Approach
NCT01982240 (5) [back to overview]Change From Baseline in CSBMs (CSBMS/Week) Over 12-week Treatment Period, Mean Replacement Approach
NCT01982240 (5) [back to overview]Change From Baseline in SBM (SBMs/Week) Over 12-week Treatment Period, Mean Replacement Approach
NCT01982240 (5) [back to overview]Change From Baseline in Stool Consistency Score Over the 12-week Treatment Period, Mean Replacement Approach
NCT01982240 (5) [back to overview]Change From Baseline in Straining Score Over 12-Week Treatment Period, Mean Replacement Approach
NCT02383758 (4) [back to overview]Mean Clinical Global Impression for Severity (CGI-S) Score
NCT02383758 (4) [back to overview]Mean Clinical Global Impression for Improvement (CGI-I) Score
NCT02383758 (4) [back to overview]Percent Continent
NCT02383758 (4) [back to overview]Percent Independence
NCT02481219 (6) [back to overview]Comparing of Completion Rate of Capsule of Two Different Bowel Preparation Methods for PillCam CCE
NCT02481219 (6) [back to overview]Excretion Rate of Capsule Within 12 Hours of Two Different Bowel Preparation Methods for PillCam CCE
NCT02481219 (6) [back to overview]Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE)
NCT02481219 (6) [back to overview]Comparing Polyp Detection Rate of Two Different Bowel Preparation Methods for PillCam CCE
NCT02481219 (6) [back to overview]Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE
NCT02481219 (6) [back to overview]Colonic Transit Time of Two Different Bowel Preparation Methods for PillCam CCE
NCT02609607 (9) [back to overview]Change From Baseline in Mean PAC-SYM Subscale Scores at 4 Weeks
NCT02609607 (9) [back to overview]Change From Baseline in SF-36 Scores at 4 Weeks
NCT02609607 (9) [back to overview]Change From Baseline in Fecal Incontinence Quality of Life (FIQL) Score at 4 Weeks
NCT02609607 (9) [back to overview]Change From Baseline In Percent of Subjects With Normal Average Stool Form at 4 Weeks
NCT02609607 (9) [back to overview]Change From Baseline in PAC-QOL Scores at 4 Weeks
NCT02609607 (9) [back to overview]Change From Baseline in Fecal Incontinence Severity Index (FISI) Score at 4 Weeks
NCT02609607 (9) [back to overview]Change From Baseline In Average Number of Fecal Incontinence Episodes at 4 Weeks
NCT02609607 (9) [back to overview]Number of Participants With 30% Improvement From Baseline in Bowel Symptoms at 4 Weeks
NCT02609607 (9) [back to overview]Change From Baseline In Average Number of Daily Bowel Movements at 4 Weeks
NCT02977286 (17) [back to overview]Average Daily Opioid Requirement [in IV Fentanyl Equivalents (mcg Per Day)]
NCT02977286 (17) [back to overview]Daily Difference in the Pre-dose and Post-dose Clinical Opioid Withdrawal Scale (COWS) Score
NCT02977286 (17) [back to overview]Daily Fluid Balance
NCT02977286 (17) [back to overview]Daily Maximal Pain Scale Score
NCT02977286 (17) [back to overview]Daily Maximal Sedation Assessment Scale (SAS) Score
NCT02977286 (17) [back to overview]Daily Presence of Delirium Using the Intensive Care Delirium Screening Checklist (ICDSC)
NCT02977286 (17) [back to overview]Days Without Mechanical Ventilation Support for Duration of ICU Stay
NCT02977286 (17) [back to overview]ICU Days Without a SBM
NCT02977286 (17) [back to overview]Abdominal Pressure Measurement
NCT02977286 (17) [back to overview]Number of Patients With Loose and Unformed or Liquid SBM
NCT02977286 (17) [back to overview]Occurrence of Lower GI Tract Paralysis (≥3 Days Without a SBM)
NCT02977286 (17) [back to overview]Occurrence of Lower GI Tract Paralysis Requiring GI/Surgical Consultation
NCT02977286 (17) [back to overview]Percentage of Daily Goal Reached for Enteral Nutrition Administration
NCT02977286 (17) [back to overview]Time to First Episode of Diarrhea
NCT02977286 (17) [back to overview]Time to First Spontaneous Bowel Movement (SBM)
NCT02977286 (17) [back to overview]Time to First Spontaneous Bowel Movement (SBM) Administration
NCT02977286 (17) [back to overview]Number of Patients That Required Use of the Study Laxative Protocol

Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 4

The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 4 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.1
Bisacodyl-0.2

[back to top]

Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 4 in the Treatment Period in Comparison to Baseline

Reduced / unchanged / increased bothersomeness of abdominal discomfort is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 4 in the treatment period

,
InterventionParticipants (Number)
Reduced bothersomenessUnchanged bothersomenessIncreased bothersomeness
Bisacodyl974632
Placebo313631

[back to top]

Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 1 in the Treatment Period in Comparison to Baseline

Reduced / unchanged / increased bothersomeness of constipation is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 1 in the treatment period

,
InterventionParticipants (Number)
Reduced bothersomenessUnchanged bothersomenessIncreased bothersomeness
Bisacodyl1684610
Placebo365125

[back to top]

Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 2 in the Treatment Period in Comparison to Baseline

Reduced / unchanged / increased bothersomeness of constipation is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 2 in the treatment period

,
InterventionParticipants (Number)
Reduced bothersomenessUnchanged bothersomenessIncreased bothersomeness
Bisacodyl1603616
Placebo354531

[back to top]

Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 3 in the Treatment Period in Comparison to Baseline

Reduced / unchanged / increased bothersomeness of constipation is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 3 in the treatment period

,
InterventionParticipants (Number)
Reduced bothersomenessUnchanged bothersomenessIncreased bothersomeness
Bisacodyl1473018
Placebo394124

[back to top]

Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Constipation at Week 4 in the Treatment Period in Comparison to Baseline

Reduced / unchanged / increased bothersomeness of constipation is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 4 in the treatment period

,
InterventionParticipants (Number)
Reduced bothersomenessUnchanged bothersomenessIncreased bothersomeness
Bisacodyl1253515
Placebo304721

[back to top]

Number of Participants With Respect to the Final Global Assessment of Efficacy by the Investigator

Final global assessment scale range: 1 (good) to 4 (bad), ordinal (NCT00526097)
Timeframe: 4 weeks

,
InterventionParticipants (Number)
GoodSatisfactoryNot satisfactoryBad
Bisacodyl15659186
Placebo26373024

[back to top]

Number of Participants With Respect to the Final Global Assessment of Efficacy by the Patient

Final global assessment scale range: 1 (good) to 4 (bad), ordinal (NCT00526097)
Timeframe: 4 weeks

,
InterventionParticipants (Number)
GoodSatisfactoryNot satisfactoryBad
Bisacodyl132582722
Placebo23354019

[back to top]

Number of Participants With Respect to the Final Global Assessment of Tolerability by the Investigator

Final global assessment scale range: 1 (good) to 4 (bad), ordinal (NCT00526097)
Timeframe: 4 weeks

,
InterventionParticipants (Number)
GoodSatisfactoryNot satisfactoryBad
Bisacodyl85844327
Placebo7531101

[back to top]

Change From Baseline for Chloride (Normalized Value)

Normalized value: the reported laboratory value is converted by linear transformation to a preferred unit and then linear-transformed with respect to the standard reference range (NCT00526097)
Timeframe: Baseline and 4 weeks

Interventionmmol/L (Mean)
Placebo0
Bisacodyl0

[back to top]

Change From Baseline for Potassium (Normalized Value)

Normalized value: the reported laboratory value is converted by linear transformation to a preferred unit and then linear-transformed with respect to the standard reference range (NCT00526097)
Timeframe: Baseline and 4 weeks

Interventionmmol/L (Mean)
Placebo0.0
Bisacodyl-0.0

[back to top]

Change From Baseline for Sodium (Normalized Value)

Normalized value: the reported laboratory value is converted by linear transformation to a preferred unit and then linear-transformed with respect to the standard reference range (NCT00526097)
Timeframe: Baseline and 4 weeks

Interventionmmol/L (Mean)
Placebo-0
Bisacodyl-0

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 1

The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 1 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.1
Bisacodyl-0.9

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 2

The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 2 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.1
Bisacodyl-0.9

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 3

The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 3 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.1
Bisacodyl-0.9

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Anorectal Obstructions/Blockade' at Week 4

The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 4 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.1
Bisacodyl-0.8

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 1

The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 1 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.0
Bisacodyl-0.2

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 2

The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 2 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo0.0
Bisacodyl-0.2

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Manual Manoeuvre' at Week 3

The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 3 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.0
Bisacodyl-0.2

[back to top]

Change From Baseline in the SF-36 Dimension 'General Health'

The dimension is a sum of 5 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health. (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-1.3
Bisacodyl0.7

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 1

The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 1 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.0
Bisacodyl-0.2

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 2

The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 2 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.0
Bisacodyl-0.2

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 3

The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 3 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.1
Bisacodyl-0.2

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Sensation of Incomplete Evacuation' at Week 4

The score on a 2-point ordinal verbal rating scale from 0 (no) to 1 (yes) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 4 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.1
Bisacodyl-0.2

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 1

The score on the 7-point Bristol Stool Form Scale from Type 1 (hard, lumpy stool) to Type 7 (watery stool) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 1 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo0.4
Bisacodyl3.0

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 2

The score on the 7-point Bristol Stool Form Scale from Type 1 (hard, lumpy stool) to Type 7 (watery stool) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 2 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo0.2
Bisacodyl2.7

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 3

The score on the 7-point Bristol Stool Form Scale from Type 1 (hard, lumpy stool) to Type 7 (watery stool) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 3 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo0.5
Bisacodyl2.8

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Stool Quality' at Week 4

The score on the 7-point Bristol Stool Form Scale from Type 1 (hard, lumpy stool) to Type 7 (watery stool) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 4 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo0.6
Bisacodyl2.6

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 1

The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 1 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.3
Bisacodyl-1.3

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 2

The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 2 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.1
Bisacodyl-1.1

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 3

The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 3 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.3
Bisacodyl-1.3

[back to top]

Change From Baseline in the Mean Score for Constipation Symptom 'Straining' at Week 4

The score on a 5-point ordinal verbal rating scale from 0 (absent) to 4 (very severe) specifying patient's symptom assessment associated with each bowel movement was averaged over the day and then averaged over the days in the corresponding week. (NCT00526097)
Timeframe: Baseline and week 4 in treatment period

InterventionScore on a scale (Least Squares Mean)
Placebo-0.5
Bisacodyl-1.2

[back to top]

Change From Baseline in the PAC-QoL Overall Score

The PAC-QoL is a 28-item (5-point Likert scale ranging from 0 (none of the time or not at all) to 4 (all of the time or extremely). Single item scores are inverted, if applicable, to ensure that a lower score indicates a better QoL (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-0.1
Bisacodyl-0.8

[back to top]

Change From Baseline in the PAC-QoL Subscale 'Physical Discomfort'

The PAC-QoL is a 28-item (5-point Likert scale ranging from 0 (none of the time or not at all) to 4 (all of the time or extremely). Single item scores are inverted, if applicable, to ensure that a lower score indicates a better QoL (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-0.2
Bisacodyl-1.0

[back to top]

Change From Baseline in the PAC-QoL Subscale 'Psychosocial Discomfort'

The PAC-QoL is a 28-item (5-point Likert scale ranging from 0 (none of the time or not at all) to 4 (all of the time or extremely). Single item scores are inverted, if applicable, to ensure that a lower score indicates a better QoL (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-0.1
Bisacodyl-0.3

[back to top]

Change From Baseline in the PAC-QoL Subscale 'Satisfaction'

The PAC-QoL is a 28-item (5-point Likert scale ranging from 0 (none of the time or not at all) to 4 (all of the time or extremely). Single item scores are inverted, if applicable, to ensure that a lower score indicates a better QoL (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-0.2
Bisacodyl-1.4

[back to top]

Change From Baseline in the PAC-QoL Subscale 'Worries and Concerns'

The PAC-QoL is a 28-item (5-point Likert scale ranging from 0 (none of the time or not at all) to 4 (all of the time or extremely). Single item scores are inverted, if applicable, to ensure that a lower score indicates a better QoL (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-0.1
Bisacodyl-0.6

[back to top]

Change From Baseline in the SF-36 Dimension 'Bodily Pain'

The dimension is a sum of 2 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health. (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-2.3
Bisacodyl-0.2

[back to top]

Number of Participants With Respect to the Final Global Assessment of Tolerability by the Patient

Final global assessment scale range: 1 (good) to 4 (bad), ordinal (NCT00526097)
Timeframe: 4 weeks

,
InterventionParticipants (Number)
GoodSatisfactoryNot satisfactoryBad
Bisacodyl125652227
Placebo38501910

[back to top]

Change From Baseline in the SF-36 Dimension 'Mental Health'

The dimension is a sum of 5 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health. (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-2.9
Bisacodyl0.6

[back to top]

Change From Baseline in the SF-36 Dimension 'Physical Functioning'

The dimension is a sum of 10 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health. (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-0.6
Bisacodyl-0.0

[back to top]

Change From Baseline in the SF-36 Dimension 'Role Limitation Due to Emotional Problems'

The dimension is a sum of 3 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health. (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-0.5
Bisacodyl0.1

[back to top]

Change From Baseline in the SF-36 Dimension 'Role Limitation Due to Physical Problems'

The dimension is a sum of 4 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health. (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-0.2
Bisacodyl0.9

[back to top]

Change From Baseline in the SF-36 Dimension 'Social Functioning'

The dimension is a sum of 2 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health. (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-2.6
Bisacodyl-1.5

[back to top]

Change From Baseline in the SF-36 Dimension 'Vitality'

The dimension is a sum of 4 single items and then transferred to a scale ranging from 0 to 100. Single item scores are inverted, if applicable, to ensure that a higher score indicates a better health. (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-1.6
Bisacodyl2.7

[back to top]

Change From Baseline in the SF-36 Mental Component Scale (MCS)

The MCS is a summary scale of the dimensions vitality, social functioning, role-emotional, and mental health. The component scale is norm-based to a standard population. A higher score indicates a better health. (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-1.0
Bisacodyl0.3

[back to top]

Change From Baseline in the SF-36 Physical Component Scale (PCS)

The PCS is a summary scale of the subscales physical functioning, role-physical, bodily pain, and general health. The component scale is norm-based to a standard population. A higher score indicates a better health. (NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionScore on a scale (Least Squares Mean)
Placebo-0.4
Bisacodyl0.3

[back to top]

Mean Number of Complete Spontaneous Bowel Movements (CSBMs) Per Week Over the 4 Weeks Treatment Period

"A Complete Spontaneous Bowel Movement (CSBM) is a complete non-rescue medication-induced stool.~The number of CSBMs in each of the 4 weeks was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer. The sum of the resulting numbers were divided by the number of weeks with data." (NCT00526097)
Timeframe: 4 Weeks

InterventionCSBMs per week (Least Squares Mean)
Placebo1.9
Bisacodyl5.2

[back to top]

Mean Number of SBMs Per Week Over the 4 Weeks Treatment Period

A Spontaneous Bowel Movement (SBM) is a non-rescue medication-induced stool. The number of SBMs in each of the 4 weeks was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer. The sum of the resulting numbers were divided by the number of weeks with data. (NCT00526097)
Timeframe: 4 Weeks

InterventionSBMs per week (Least Squares Mean)
Placebo5.1
Bisacodyl10.0

[back to top]

Number of CSBMs at Week 1

The number of CSBMs at week 1 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer. (NCT00526097)
Timeframe: Week 1 in treatment period

InterventionCSBMs per week (Least Squares Mean)
Placebo2.0
Bisacodyl6.3

[back to top]

Number of CSBMs at Week 2

The number of CSBMs at week 2 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer. (NCT00526097)
Timeframe: Week 2 in treatment period

InterventionCSBMs per week (Least Squares Mean)
Placebo1.4
Bisacodyl4.9

[back to top]

Number of CSBMs at Week 3

The number of CSBMs at week 3 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer. (NCT00526097)
Timeframe: Week 3 in treatment period

InterventionCSBMs per week (Least Squares Mean)
Placebo1.8
Bisacodyl4.6

[back to top]

Number of CSBMs at Week 4

The number of CSBMs at week 4 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer. (NCT00526097)
Timeframe: Week 4 in treatment period

InterventionCSBMs per week (Least Squares Mean)
Placebo1.7
Bisacodyl4.3

[back to top]

Number of Participants Using Rescue Medication at Week 1 in the Treatment Period

(NCT00526097)
Timeframe: Week 1 in the treatment period

InterventionParticipants (Number)
Placebo2
Bisacodyl1

[back to top]

Number of Participants Using Rescue Medication at Week 2 in the Treatment Period

(NCT00526097)
Timeframe: Week 2 in the treatment period

InterventionParticipants (Number)
Placebo10
Bisacodyl4

[back to top]

Number of Participants Using Rescue Medication at Week 3 in the Treatment Period

(NCT00526097)
Timeframe: Week 3 in the treatment period

InterventionParticipants (Number)
Placebo9
Bisacodyl1

[back to top]

Number of Participants Using Rescue Medication at Week 4 in the Treatment Period

(NCT00526097)
Timeframe: Week 4 in the treatment period

InterventionParticipants (Number)
Placebo12
Bisacodyl6

[back to top]

Number of Participants Using Rescue Medication Over the 4 Weeks Treatment Period

(NCT00526097)
Timeframe: 4 weeks

InterventionParticipants (Number)
Placebo21
Bisacodyl8

[back to top]

Number of Participants With a Mean of at Least 1 CSBM a Day Over the 4 Weeks Treatment Period

(NCT00526097)
Timeframe: 4 weeks

InterventionParticipants (Number)
Placebo2
Bisacodyl70

[back to top]

Number of Participants With a Mean of at Least 3 CSBMs a Week Over the 4 Weeks Treatment Period

(NCT00526097)
Timeframe: 4 weeks

InterventionParticipants (Number)
Placebo32
Bisacodyl161

[back to top]

Number of Participants With an Increase of at Least 1 CSBM at Week 1 Compared to Baseline

(NCT00526097)
Timeframe: Baseline and week 1 in treatment period

InterventionParticipants (Number)
Placebo57
Bisacodyl204

[back to top]

Number of Participants With an Increase of at Least 1 CSBM at Week 2 Compared to Baseline

(NCT00526097)
Timeframe: Baseline and week 2 in treatment period

InterventionParticipants (Number)
Placebo43
Bisacodyl178

[back to top]

Number of Participants With an Increase of at Least 1 CSBM at Week 3 Compared to Baseline

(NCT00526097)
Timeframe: Baseline and week 3 in treatment period

InterventionParticipants (Number)
Placebo51
Bisacodyl163

[back to top]

Number of Participants With an Increase of at Least 1 CSBM at Week 4 Compared to Baseline

(NCT00526097)
Timeframe: Baseline and week 4 in treatment period

InterventionParticipants (Number)
Placebo52
Bisacodyl148

[back to top]

Number of Participants With an Increase of at Least 1 in the Mean Number of CSBMs Per Week Over the 4 Weeks Treatment Period Compared to Baseline

(NCT00526097)
Timeframe: Baseline and 4 weeks

InterventionParticipants (Number)
Placebo47
Bisacodyl196

[back to top]

Number of Premature Withdrawals at Week 1 in the Treatment Period

(NCT00526097)
Timeframe: Week 1 in the treatment period

InterventionParticipants (Number)
Placebo3
Bisacodyl25

[back to top]

Number of Premature Withdrawals at Week 2 in the Treatment Period

(NCT00526097)
Timeframe: Week 2 in the treatment period

InterventionParticipants (Number)
Placebo3
Bisacodyl11

[back to top]

Number of Premature Withdrawals at Week 3 in the Treatment Period

(NCT00526097)
Timeframe: Week 3 in the treatment period

InterventionParticipants (Number)
Placebo4
Bisacodyl9

[back to top]

Number of Premature Withdrawals at Week 4 in the Treatment Period

(NCT00526097)
Timeframe: Week 4 in the treatment period

InterventionParticipants (Number)
Placebo0
Bisacodyl6

[back to top]

Number of Premature Withdrawals Over the 4 Weeks Treatment Period

(NCT00526097)
Timeframe: 4 weeks

InterventionParticipants (Number)
Placebo10
Bisacodyl51

[back to top]

Number of SBMs at Week 1

The number of SBMs at week 1 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer. (NCT00526097)
Timeframe: Week 1 in treatment period

InterventionSBMs per week (Least Squares Mean)
Placebo5.3
Bisacodyl12.1

[back to top]

Number of SBMs at Week 2

The number of SBMs at week 2 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer. (NCT00526097)
Timeframe: Week 2 in treatment period

InterventionSBMs per week (Least Squares Mean)
Placebo4.9
Bisacodyl9.6

[back to top]

Number of SBMs at Week 3

The number of SBMs at week 3 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer. (NCT00526097)
Timeframe: Week 3 in treatment period

InterventionSBMs per week (Least Squares Mean)
Placebo4.8
Bisacodyl8.6

[back to top]

Number of SBMs at Week 4

The number of SBMs at week 4 was divided by the number of days where data were available in this week, multiplied by 7 and rounded off to the next integer. (NCT00526097)
Timeframe: Week 4 in treatment period

InterventionSBMs per week (Least Squares Mean)
Placebo4.0
Bisacodyl7.8

[back to top]

Time to the First SBM Following the First Dose of Study Medication (SM)

The time to the first SBM following the first dose of SM was captured by the eDiary. The time was censored by the time of intake of rescue medication (RM), the time of premature discontinuation or the end of treatment whatever was minimal. (NCT00526097)
Timeframe: Time of first dose of SM up to 4 weeks

InterventionHours (Median)
Placebo19
Bisacodyl12

[back to top]

Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 1 in the Treatment Period in Comparison to Baseline

Improved / unchanged / worsened overall satisfaction is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (A very great deal satisfied) to 4 (Not at all satisfied) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 1 in the treatment period

,
InterventionParticipants (Number)
Improved overall satisfactionUnchanged overall satisfactionWorsened overall satisfaction
Bisacodyl1534526
Placebo444622

[back to top]

Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 2 in the Treatment Period in Comparison to Baseline

Improved / unchanged / worsened overall satisfaction is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (A very great deal satisfied) to 4 (Not at all satisfied) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 2 in the treatment period

,
InterventionParticipants (Number)
Improved overall satisfactionUnchanged overall satisfactionWorsened overall satisfaction
Bisacodyl1633712
Placebo414822

[back to top]

Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 3 in the Treatment Period in Comparison to Baseline

Improved / unchanged / worsened overall satisfaction is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (A very great deal satisfied) to 4 (Not at all satisfied) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 3 in the treatment period

,
InterventionParticipants (Number)
Improved overall satisfactionUnchanged overall satisfactionWorsened overall satisfaction
Bisacodyl1533111
Placebo444317

[back to top]

Number of Participants With Improved, Unchanged or Worsened Overall Satisfaction With Bowel Habits at Week 4 in the Treatment Period in Comparison to Baseline

Improved / unchanged / worsened overall satisfaction is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (A very great deal satisfied) to 4 (Not at all satisfied) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 4 in the treatment period

,
InterventionParticipants (Number)
Improved overall satisfactionUnchanged overall satisfactionWorsened overall satisfaction
Bisacodyl135328
Placebo374714

[back to top]

Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 1 in the Treatment Period in Comparison to Baseline

Reduced / unchanged / increased bothersomeness of abdominal bloating is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 1 in the treatment period

,
InterventionParticipants (Number)
Reduced bothersomenessUnchanged bothersomenessIncreased bothersomeness
Bisacodyl1365929
Placebo334732

[back to top]

Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 2 in the Treatment Period in Comparison to Baseline

Reduced / unchanged / increased bothersomeness of abdominal bloating is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 2 in the treatment period

,
InterventionParticipants (Number)
Reduced bothersomenessUnchanged bothersomenessIncreased bothersomeness
Bisacodyl1424327
Placebo314634

[back to top]

Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 3 in the Treatment Period in Comparison to Baseline

Reduced / unchanged / increased bothersomeness of abdominal bloating is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 3 in the treatment period

,
InterventionParticipants (Number)
Reduced bothersomenessUnchanged bothersomenessIncreased bothersomeness
Bisacodyl1294917
Placebo274532

[back to top]

Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Bloating at Week 4 in the Treatment Period in Comparison to Baseline

Reduced / unchanged / increased bothersomeness of abdominal bloating is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 4 in the treatment period

,
InterventionParticipants (Number)
Reduced bothersomenessUnchanged bothersomenessIncreased bothersomeness
Bisacodyl1074919
Placebo254627

[back to top]

Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 1 in the Treatment Period in Comparison to Baseline

Reduced / unchanged / increased bothersomeness of abdominal discomfort is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 1 in the treatment period

,
InterventionParticipants (Number)
Reduced bothersomenessUnchanged bothersomenessIncreased bothersomeness
Bisacodyl936269
Placebo374629

[back to top]

Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 2 in the Treatment Period in Comparison to Baseline

Reduced / unchanged / increased bothersomeness of abdominal discomfort is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 2 in the treatment period

,
InterventionParticipants (Number)
Reduced bothersomenessUnchanged bothersomenessIncreased bothersomeness
Bisacodyl1046741
Placebo294933

[back to top]

Number of Participants With Reduced, Unchanged or Increased Bothersomeness With Abdominal Discomfort at Week 3 in the Treatment Period in Comparison to Baseline

Reduced / unchanged / increased bothersomeness of abdominal discomfort is a decreased / unchanged / increased score on a 5-point ordinal VRS: 0 (Not at all bothersome) to 4 (A very great deal bothersome) at the corresponding week in comparison to baseline (NCT00526097)
Timeframe: Baseline and week 3 in the treatment period

,
InterventionParticipants (Number)
Reduced bothersomenessUnchanged bothersomenessIncreased bothersomeness
Bisacodyl1016331
Placebo343337

[back to top]

Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale

"Cleansing was scored with a four point scale used in previous bowel cleansing studies where 4 = excellent (no more than small bits of adherent feces/fluid); 3 = good (small amounts of feces or fluid not interfering with the exam); 2 = fair (enough feces or fluid to prevent a completely reliable exam); 1 = poor (large amounts of fecal residue requiring additional cleansing). For the primary efficacy endpoint (preparation success), grades of 4 and 3 were considered a success and grades of 2 or 1 were considered a failure." (NCT00857272)
Timeframe: during colonoscopy

Interventionpercent of participants (Number)
HalfLytely With 5mg Bisacodyl77.6
HalfLytely With 10mg Bisacodyl80.1

[back to top]

The Cleanliness of the Prep as Measured by the Ottawa Scale

Bowel cleansing was evaluated with the Ottawa bowel preparation scale by each endoscopist during the endoscopy. Neither the endoscopist nor the endoscopy nurse was aware of the bowel preparation used prior to the colonoscopy. The Ottawa bowel preparation scale is a validated tool and was used in this study to provide a reliable quality assessment of the bowel preparation used for colonoscopy. This validated scale rates each section of the colon, the right, the mid, and the rectosigmoid colon, on a 5-point scale (0-4), as well as a global 3-point rating for overall colonic fluid (0-2). The total score ranges from 0 to 14. An excellent preparation with little fluid would score 0-3, a good preparation 4-6, while scores higher than 7 would indicate progressively worsening bowel preparations. A completely unprepared colon would score 11-14, depending on the amount of colonic fluid. (NCT00953017)
Timeframe: measured at the time of colonoscopy

InterventionOttawa Scale (Mean)
Miralax Plus Amitiza6.3
Miralax Plus Dulcolax6.8
Miralax6.9
Golytely (Polyethylene Glycol)5.1

[back to top]

Procedure Time

total colonoscopy procedure time (NCT00953017)
Timeframe: measured at the time of colonoscopy

Interventionminutes (Mean)
Miralax Plus Amitiza21.3
Miralax Plus Dulcolax19.3
Miralax20
Golytely (Polyethylene Glycol)18.3

[back to top]

Polyps Detected

Number of polyps (NCT00953017)
Timeframe: measured at the time of colonoscopy

Interventionpolyps (Number)
Miralax Plus Amitiza128
Miralax Plus Dulcolax92
Miralax90
Golytely (Polyethylene Glycol)101

[back to top]

Patient Satisfaction With the Prep Measured by 5 Point Likert Scale

patient satisfaction based on a Likert Scale from 0-5 (5 being completely satisfied and 0 being not satisfied) (NCT00953017)
Timeframe: measured at check in to colonoscopy

Interventionunits on a scale (Mean)
Miralax Plus Amitiza3.8
Miralax Plus Dulcolax4.1
Miralax4.0
Golytely (Polyethylene Glycol)3.2

[back to top]

The Quality of the Colon Preparation Will be Graded Using the Boston Bowel Preparation Scale

The Boston Bowel Preparation Scale measures cleanliness of the colon on a scale of 0 (very poor) to 9 (excellent). (NCT01063049)
Timeframe: After Colonoscopy

Interventionunits on a scale (Mean)
Nulytely7.86
Gatorade/Miralax + Placebo8.05
Gatorade/Miralax + Bisacodyl7.99

[back to top]

The Ottawa Scale for Colonoscopy Preparation Will be Reported and Compared Among the 3 Groups to Allow for Comparisons to Some of the Older Literature

Ottawa scale measures colon cleanliness on a scale from 14 (very poor) to 0 (excellent). (NCT01063049)
Timeframe: After Colonoscopy

Interventionunits on a scale (Mean)
Nulytely2.80
Gatorade/Miralax + Placebo2.58
Gatorade/Miralax + Bisacodyl2.71

[back to top]

Percentage of Participants Classified as Successes (Excellent, Good and Fair Ratings) According to the Ottawa Scale As Assessed by a Blinded Gastroenterologist

Overall colon cleansing was assessed by a blinded gastroenterologist during the colonoscopy using the Ottawa scale, a 5-step rating scale: inadequate, poor, fair, good, and excellent. Excellent is defined as mucosal detail clearly visible; if fluid is present, it is clear and there is almost no stool residue. Good - some turbid fluid or stool residue but mucosal detail still visible; washing and suctioning is not necessary. Fair - turbid fluid or stool residue obscuring mucosal detail. However, mucosal detail becomes visible with suctioning and washing is not necessary. (NCT01073930)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
Ascending colonMid colonRecto-sigmoid colonOverall: ascending, mid, and recto-sigmoid colon
HalfLytely78.885.987.275.4
PICOPREP89.592.492.486.8

[back to top]

Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: How Easy or Difficult Was It To Consume the Study Drug?

Participants answered the question above on Day 2 prior to the colonoscopy procedure. Answers were on a 5-point scale: very easy, easy, tolerable, difficult, very difficult (NCT01073930)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
Very easyEasyTolerableDifficultVery difficult
HalfLytely8.120.947.014.99.1
PICOPREP57.931.59.61.00

[back to top]

Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Please Describe Your Overall Experience With the Study Preparation

Participants answered the question above on Day 2 prior to the colonoscopy procedure. Answers were on a 5-point scale: Excellent, Good, Fair, Poor, Bad (NCT01073930)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
ExcellentGoodFairPoorBad
HalfLytely16.642.928.77.14.7
PICOPREP46.845.26.61.00.3

[back to top]

Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: The Taste of This Study Preparation Was

Participants answered the question above on Day 2 prior to the colonoscopy procedure. Answers were on a 5-point scale: Excellent, Good, Tolerable, Poor, Bad (NCT01073930)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
ExcellentGoodTolerablePoorBad
HalfLytely2.718.956.213.19.1
PICOPREP23.450.525.70.30

[back to top]

Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Were You Able to Consume the Entire Prep As Instructed?

Participants answered the question above on Day 2 prior to the colonoscopy procedure. Answers were on a 2-point scale: yes, no (NCT01073930)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
YesNo
HalfLytely89.910.1
PICOPREP99.01.0

[back to top]

Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Would You Ask Your Doctor for This Preparation Again if You Need Another Colonoscopy in the Future?

Participants answered the question above on Day 2 prior to the colonoscopy procedure. Answers were on a 2-point scale: yes, no (NCT01073930)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
YesNo
HalfLytely54.745.3
PICOPREP96.04.0

[back to top]

Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Would You Refuse the Same Preparation Again if it Were to be Prescribed to You in the Future?

Participants answered the question above on Day 2 prior to the colonoscopy procedure. Answers were on a 2-point scale: yes, no (NCT01073930)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
YesNo
HalfLytely13.586.5
PICOPREP1.798.3

[back to top]

Percentage of Participants Classified as Successes (Excellent and Good Ratings) According to the Aronchick Scale As Assessed by a Blinded Gastroenterologist

Overall colon cleansing was assessed by a blinded gastroenterologist during the colonoscopy using the Aronchick scale. The Aronchick scale is a 4-step rating scale: inadequate, fair, good, and excellent. Excellent is defined as >90% of mucosa seen, mostly liquid stool, minimal suctioning needed for adequate visualization. Good is defined as >90% of mucosa seen, mostly liquid stool, significant suctioning needed for adequate visualization. (NCT01073930)
Timeframe: Day 2

Interventionpercentage of participants (Number)
PICOPREP84.2
HalfLytely74.4

[back to top]

Participants With Treatment-Emergent Adverse Events (TEAEs)

Counts of participants who had TEAEs are summarized in a variety of categories. Severity and relatedness to study drug are in the opinion of the investigator. Severity is rated on a 3-point scale: mild (awareness of signs or symptoms, but no disruption of usual activity), moderate (event sufficient to affect usual activity), and severe (inability to work or perform usual activities). Only severe TEAEs are summarized. Relatedness is assessed on a 4-point scale: unrelated, unlikely, possibly and probably. Both possibly and probably answers are reported as 'related' to study medication. (NCT01073930)
Timeframe: up to one month

,
Interventionparticipants (Number)
Any TEAEDeathSerious AETEAEs leading to discontinuation of study drugSevere TEAEsRelated TEAEs
HalfLytely217021626
PICOPREP211010219

[back to top]

Percentage of Participants Classified as Successes (Excellent and Good Ratings) According to the Aronchick Scale As Assessed by a Blinded Gastroenterologist

Overall colon cleansing was assessed by a blinded gastroenterologist during the colonoscopy using the Aronchick scale. The Aronchick scale is a 4-step rating scale: inadequate, fair, good, and excellent. Excellent is defined as >90% of mucosa seen, mostly liquid stool, minimal suctioning needed for adequate visualization. Good is defined as >90% of mucosa seen, mostly liquid stool, significant suctioning needed for adequate visualization. (NCT01073943)
Timeframe: Day 2

Interventionpercentage of participants (Number)
PicoPrep83.0
HalfLytely79.7

[back to top]

Percentage of Participants Classified as Successes (Excellent, Good and Fair Ratings) For Ascending Colon Cleansing According to the Ottawa Scale As Assessed by a Blinded Gastroenterologist

Cleansing of the ascending colon was assessed by a blinded gastroenterologist during the colonoscopy using the Ottawa scale, a 5-step rating scale: inadequate, poor, fair, good, and excellent. Excellent is defined as mucosal detail clearly visible; if fluid is present, it is clear and there is almost no stool residue. Good - some turbid fluid or stool residue but mucosal detail still visible; washing and suctioning is not necessary. Fair - turbid fluid or stool residue obscuring mucosal detail. However, mucosal detail becomes visible with suctioning and washing is not necessary. (NCT01073943)
Timeframe: Day 2

Interventionpercentage of participants (Number)
PicoPrep81.3
HalfLytely84.0

[back to top]

Participants With Treatment-Emergent Adverse Events (TEAEs)

Counts of participants who had TEAEs are summarized in a variety of categories. Severity and relatedness to study drug are in the opinion of the investigator. Severity is rated on a 3-point scale: mild (awareness of signs or symptoms, but no disruption of usual activity), moderate (event sufficient to affect usual activity), and severe (inability to work or perform usual activities). Only severe TEAEs are summarized. Relatedness is assessed on a 4-point scale: unrelated, unlikely, possibly and probably. Both possibly and probably answers are reported as 'related' to study medication. (NCT01073943)
Timeframe: up to one month

,
Interventionparticipants (Number)
Any TEAEDeathsSerious AETEAEs leading to discontinuation of study drugSevere TEAEsRelated TEAEs
HalfLytely241011629
PicoPrep218020533

[back to top]

Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Would You Ask Your Doctor for This Preparation Again if You Need Another Colonoscopy in the Future?

Participants answered the question above on Day 2 prior to the colonoscopy procedure. Answers were on a 2-point scale: yes, no (NCT01073943)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
YesNo
HalfLytely59.440.6
PicoPrep93.26.8

[back to top]

Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Were You Able to Consume the Entire Prep As Instructed?

Participants answered the question above on Day 2 prior to the colonoscopy procedure. Answers were on a 2-point scale: yes, no (NCT01073943)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
YesNo
HalfLytely92.37.7
PicoPrep99.70.3

[back to top]

Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: The Taste of This Study Preparation Was

Participants answered the question above on Day 2 prior to the colonoscopy procedure. Answers were on a 5-point scale: Excellent, Good, Tolerable, Poor, Bad (NCT01073943)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
ExcellentGoodTolerablePoorBad
HalfLytely4.023.852.312.17.7
PicoPrep25.648.123.91.70.7

[back to top]

Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Please Describe Your Overall Experience With the Study Preparation

Participants answered the question above on Day 2 prior to the colonoscopy procedure. Answers were on a 5-point scale: Excellent, Good, Fair, Poor, Bad (NCT01073943)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
ExcellentGoodFairPoorBad
HalfLytely19.148.725.53.43.4
PicoPrep45.543.89.20.70.7

[back to top]

Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: How Easy or Difficult Was It To Consume the Study Drug?

Participants answered the question above on Day 2 prior to the colonoscopy procedure. Answers were on a 5-point scale: very easy, easy, tolerable, difficult, very difficult (NCT01073943)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
Very easyEasyTolerableDifficultVery difficult
HalfLytely16.121.145.311.75.7
PicoPrep58.429.011.61.00

[back to top]

Percentage of Participants Classified as Successes (Excellent, Good and Fair Ratings) For Colon Cleansing According to the Ottawa Scale As Assessed by a Blinded Gastroenterologist

Colon cleansing was assessed by a blinded gastroenterologist during the colonoscopy using the Ottawa scale, a 5-step rating scale: inadequate, poor, fair, good, and excellent. See Outcome #2 for definitions of the scale. Assessment of mid colon, recto-sigmoid, and overall (ascending, mid, and recto-sigmoid) cleansing is summarized here. (NCT01073943)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
Mid-colonRecto-sigmoid colonOverall: ascending, mid, and recto-sigmoid colon
HalfLytely88.789.078.0
PicoPrep93.292.278.9

[back to top]

Percentage of Participants' Responses to the Acceptability and Tolerability Questionnaire: Would You Refuse the Same Preparation Again if it Were to be Prescribed to You in the Future?

Participants answered the question above on Day 2 prior to the colonoscopy procedure. Answers were on a 2-point scale: yes, no (NCT01073943)
Timeframe: Day 2

,
Interventionpercentage of participants (Number)
YesNo
HalfLytely14.485.6
PicoPrep4.895.2

[back to top]

Measure of Patients Who Develop (Tolerance)Side Effects of Taking Bowel Preparations.

Number of Participants Who Developed Side Effects of Taking Bowel Preparations (NCT01533688)
Timeframe: 24 hours

InterventionParticipants (Count of Participants)
Golytely + Placebo24
Golytely Split+Placebo28
Golytely Split+Bisacodyl28

[back to top]

Measure the % of Participants With Effective (How Well the Colon is Cleansed Using the Validated Boston Bowel Preparation Scale) for Various Bowel Preparations for Colonoscopy.

The investigators will measure the number/% of participants who will have good to excellent bowel preparations defined by the Boston Bowel Prep Scale(BBPS) with a score of 6 or more, rated by blinded colonoscopist. (NCT01533688)
Timeframe: Day 1

InterventionParticipants (Count of Participants)
Golytely + Placebo42
Golytely Split + Placebo50
Golytely Split + Bisacodyl47

[back to top]

Number of Participants With Inflammation of the Esophageal Mucosa

Participants underwent endoscopic examination of the esophageal mucosa at Visit 2 and Visit 3. Measurements were based on 0-3 Likert Scale Scores: 0 = No inflammation (no erythema, no erosion/ulceration); 1 = Mild inflammation (erythema without erosion/ulceration); 2 = Moderate inflammation (erythema with erosion); 3 = Severe inflammation (erythema with ulceration). (NCT01885104)
Timeframe: Visit 2 (Day 1) and Visit 3 (Day 17 ± 2 days), up to 19 days after start of treatment

,
InterventionParticipants (Number)
Visit 2: 0=No inflammationVisit 2: 1=Mild inflammationVisit 2: 2=Moderate inflammationVisit 2: 3=Severe inflammationVisit 2: Not evaluatedVisit 3: 0=No inflammationVisit 3: 1=Mild inflammationVisit 3: 2=Moderate inflammationVisit 3: 3=Severe inflammationVisit 3: Not evaluated
PEG 3350310000262102
Placebo340000291301

[back to top]

Number of Participants With Inflammation of the Oral Mucosa

Participants underwent visual examination of the oral muscosa at Visit 2 and Visit 3. Measurements were based on 0-3 Likert Scale Scores: 0 = No inflammation (no erythema, no erosion/ulceration); 1 = Mild inflammation (erythema without erosion/ulceration); 2 = Moderate inflammation (erythema with erosion); 3 = Severe inflammation (erythema with ulceration). (NCT01885104)
Timeframe: Visit 2 (Day 1) and Visit 3 (Day 17 ± 2 days), up to 19 days after start of treatment

,
InterventionParticpants (Number)
Visit 2: 0=No inflammationVisit 2: 1=Mild inflammationVisit 2: 2=Moderate inflammationVisit 2: 3=Severe inflammationVisit 2: Not evaluatedVisit 3: 0=No inflammationVisit 3: 1=Mild inflammationVisit 3: 2=Moderate inflammationVisit 3: 3=Severe inflammationVisit 3: Not evaluated
PEG 3350310000290002
Placebo340000330001

[back to top]

Compared Colonic Motility Index From Fasting to Post Octreotide Infusion

"Colonic motility was measured using a solid-state catheter. The catheter had 36 sensors spaced 5-cm apart for the first 15 sensors and 1-cm apart for the remaining sensors. Pressures were transmitted to a transducer and recorded on a personal computer system (Medical Measurement Systems USA, Dover, NH).~Motility index (MI) was calculated using the Medical Measurement Systems computer program. The MI represents the area under the curve of the pressure tracing for a certain period (21). The MI was calculated for each channel. The MIs from all of the channels were then averaged to give each patient 1 average MI for the particular period under study. In this study, MI was calculated for the periods of 15, 30, and 45 minutes before and after infusion of octreotide. MI is reported as millimeters of mercury (mmHg) per 15, 30, or 45 minutes." (NCT01917773)
Timeframe: Average MI for all patients was calculated over 15-minutes, 30-minutes and 45- minutes before and after administration of octreotide.

,,
Interventionmm Hg (Mean)
pre-octreotidepost-octreotide
15 Minutes6.035.32
30 Minutes6.896.71
45 Minutes7.737.53

[back to top]

Number of Durable Overall CSBM Responders , Mean Replacement Approach

A durable overall CSBM responder was defined as a weekly CSBM responder for at least 9 of the 12 treatment weeks, included at least 3 of the last 4 weeks. A CSBM weekly responder was defined as a patient who has ≥ 3 Complete Spontaneous Bowel Movements (CSBMs) per week and an increase from baseline of ≥1 CSBM for that week. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation. (NCT01982240)
Timeframe: 12-week Treatment Period

InterventionParticipants (Count of Participants)
Placebo46
Plecanatide 3.0 mg95
Plecanatide 6.0 mg86

[back to top]

Change From Baseline in CSBMs (CSBMS/Week) Over 12-week Treatment Period, Mean Replacement Approach

A Complete Spontaneous Bowel Movement (CSBM) was a Bowel Movement (BM) that occurred in the absence of laxative use within 24 hours of the BM and the patient reported a feeling of complete evacuation. A weekly responder had 3 or more CSBMs and an increase of at least one CSBM from baseline in the same week. (NCT01982240)
Timeframe: 12-Week Treatment Period

,,
InterventionCSBMs per week (Mean)
BaselineWeek 12 change from baseline
Placebo0.391.45
Plecanatide 3.0 mg0.322.68
Plecanatide 6.0 mg0.322.39

[back to top]

Change From Baseline in SBM (SBMs/Week) Over 12-week Treatment Period, Mean Replacement Approach

The change from baseline in the number of Spontaneous Bowel Movement (SBM) over the 12-week Treatment Period was assessed. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly SBM totals were derived from the daily diary entries reported during the Treatment Period in the BM and Symptom Diary. (NCT01982240)
Timeframe: 12-Week Treatment Period

,,
InterventionSBMs per week (Mean)
BaselineWeek 12 change from baseline
Placebo2.181.37
Plecanatide 3.0 mg1.973.30
Plecanatide 6.0 mg1.823.24

[back to top]

Change From Baseline in Stool Consistency Score Over the 12-week Treatment Period, Mean Replacement Approach

"The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale [BSFS] from 1 to 7.~= separate hard lumps like nuts (difficult to pass)~= sausage shaped but lumpy~= like a sausage but with cracks on its surface~= like a sausage or snake, smooth and soft~= soft blobs with clear-cut edges (passed easily)~= fluffy pieces with ragged edges, a mushy stool~= watery, no solid pieces (entirely liquid)" (NCT01982240)
Timeframe: 12-Week Treatment Period

,,
Interventionscore on a scale (Mean)
BaselineWeek 12 change from baseline
Placebo2.560.83
Plecanatide 3.0 mg2.521.56
Plecanatide 6.0 mg2.591.47

[back to top]

Change From Baseline in Straining Score Over 12-Week Treatment Period, Mean Replacement Approach

Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly average straining score was derived from the straining scores reported during the Treatment Period in the Daily Symptom Diary. The severity of straining during bowel movements was assessed on a 5-point Likert scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe. (NCT01982240)
Timeframe: 12-Week Treatment Period

,,
Interventionscore on a scale (Mean)
BaselineWeek 12 change from baseline
Placebo2.30-0.95
Plecanatide 3.0 mg2.31-0.70
Plecanatide 6.0 mg2.28-1.00

[back to top]

Mean Clinical Global Impression for Severity (CGI-S) Score

An independent evaluator (IE) will use the parent target problem (PTP) interview to help caregivers estimate the frequency of encopresis as well as its impact on the family. From this description, the IE (who will be blind to treatment assignment) will generate a brief narrative describing the participant's encopresis. This narrative will be used by the IE to rate the overall severity on the 7-point Clinical Global Impression for Severity (CGI-S). Clinical Global Impression of Severity (CGI-S) Scale is a clinician's assessment of patient's severity of illness. The score ranges from 1 = normal, not at all ill to 7 = among the most extremely ill patients (NCT02383758)
Timeframe: Baseline, Post-Intervention (Week 6), Post-Intervention (Week 10)

,
Interventionunits on a scale (Mean)
BaselinePost-Intervention (Week 6)Post-Intervention (Week 10)
Treatment Program5.45.04.3
Waitlist Control5.25.04.9

[back to top]

Mean Clinical Global Impression for Improvement (CGI-I) Score

An independent evaluator (IE) will use the parent target problem (PTP) interview to help caregivers estimate the frequency of encopresis as well as its impact on the family. From this description, the IE (who will be blind to treatment assignment) will generate a brief narrative describing the participant's encopresis. This narrative will be used by the IE to rate the overall severity on the 7-point Clinical Global Impression for Improvement (CGI-I). Clinical Global Impression for Improvement (CGI-I) Scale is a clinician's assessment of a patient's change in condition from baseline.The score ranges from 0 = not assessed, 1 = very much improved, through 7 = very much worse. (NCT02383758)
Timeframe: Post-Intervention (Week 6), Post-Intervention (Week 10)

,
Interventionunits on a scale (Mean)
Post-Intervention (Week 6)Post-Intervention (Week 10)
Treatment Program3.02.1
Waitlist Control3.83.6

[back to top]

Percent Continent

The percentage of participant's with continent bowel movements (control of passage of stool from the bowel). (NCT02383758)
Timeframe: Baseline, Post-Intervention (Week 2) , Follow Up (Week 4)

,
Interventionpercentage of participants (Number)
BaselinePost-Intervention (Week 2)Follow Up (Week 4)
Treatment Program065
Waitlist Control000

[back to top]

Percent Independence

Percent independence is the percentage of independent bowel movements recorded by a caregiver. A continent bowel movement without the use of any medications will constitute an independent bowel movement. (NCT02383758)
Timeframe: Baseline, Post-Intervention (Week 2) , Follow Up (Week 4)

,
Interventionpercentage of participants (Number)
BaselinePost-Intervention (Week 2)Follow Up (week 4)
Treatment Program005
Waitlist Control000

[back to top]

Comparing of Completion Rate of Capsule of Two Different Bowel Preparation Methods for PillCam CCE

Will be assessed from RAPID video in total and by segment (NCT02481219)
Timeframe: an expected average of 3 weeks from study procedure

Interventionpercentage of participants (Number)
Bowel Preparation Regimen -Control76.9
Bowel Preparation Regimen-Test90.9

[back to top]

Excretion Rate of Capsule Within 12 Hours of Two Different Bowel Preparation Methods for PillCam CCE

Will be assesses by applicable case report form (CRF) (NCT02481219)
Timeframe: an expected average of 3 weeks from study procedure

Interventionpercentage of participants (Number)
Bowel Preparation Regimen -Control80.4
Bowel Preparation Regimen-Test90.9

[back to top]

Bowel Cleansing Level of Two Different Bowel Preparation Methods for PillCam® Colon Capsule Endoscopy (CCE)

The primary endpoint is the bowel cleansing level, as determined by a standardized 4-point grading scale, assessed in total and by segment (cecum, ascending, transverse, descending/sigmoid, and rectum). (NCT02481219)
Timeframe: Within two weeks of study procedure

,
Interventionpercentage of particpants (Number)
Overall Excellent cleansingCecum Excellent cleansingAscending Excellent cleansingTransverse Excellent cleansingDescending Excellent cleansingRectum Excellent cleansingOverall Good cleansingCecum Good cleansingAscending Good cleansingTransverse Good cleansingDescending Good cleansingRectum Good cleansingOverall Fair cleansingCecum Fair cleansingAscending Fair cleansingTransverse Fair cleansingDescending Fair cleansingRectum Fair cleansingOverall Poor cleansingCecum Poor cleansingAscending Poor cleansingTransverse Poor cleansingDescending Poor cleansingRectum Poor cleansing
Bowel Preparation Regimen -Control6.814.012.210.69.5070.554.063.361.773.856.122.730.022.527.716.746.502.02.0002.4
Bowel Preparation Regimen-Test16.714.618.214.618.510.059.352.760.060.063.052.024.130.921.825.518.536.001.80002.0

[back to top]

Comparing Polyp Detection Rate of Two Different Bowel Preparation Methods for PillCam CCE

Will be assessed from RAPID video in total and by segment (NCT02481219)
Timeframe: an expected average of 3 weeks from study procedure

,
Interventionpercentage of participants (Number)
Overall (any size)Cecum (any size)Ascending (any size)Transverse (any size)Descending (any size)rectum (any size)Overall (polyps ≥6mm)Cecum (polyps ≥6mm)Ascending (polyps ≥6mm)Transverse (polyps ≥6mm)Descending (polyps ≥6mm)Rectum (polyps ≥6mm)Overall (polyps ≥10mm)Cecum Overall (polyps ≥10mm)Ascending Overall (polyps ≥10mm)Transverse (polyps ≥10mm)Descending (polyps ≥10mm)Rectum (polyps ≥10mm)
Bowel Preparation Regimen -Control46.86.014.04.331.924.421.32.02.04.312.87.38.502.004.34.9
Bowel Preparation Regimen-Test58.214.69.17.329.132.036.412.73.67.316.46.014.67.33.61.83.62.0

[back to top]

Adverse Events Rate Between Two Different Bowel Preparation Methods for PillCam CCE

Will be assesses by applicable CRF (NCT02481219)
Timeframe: Adverse Events (AE) were collected starting from the screening visit and until 5-9 days following the PillCam procedure day.

Interventionpercentage of participants with >1 AE (Number)
Bowel Preparation Regimen -Control3.4
Bowel Preparation Regimen-Test19.4

[back to top]

Colonic Transit Time of Two Different Bowel Preparation Methods for PillCam CCE

Colonic transit time of two different bowel preparation was assessed from RAPID video in total and by segment (NCT02481219)
Timeframe: an expected average of 3 weeks from study procedure

Interventionhours (Median)
Bowel Preparation Regimen - Control2.8
Bowel Preparation Regimen-Test2.4

[back to top]

Change From Baseline in Mean PAC-SYM Subscale Scores at 4 Weeks

The Patient Assessment of Constipation Symptom Questionnaire (PAC-SYM) is a validated measure of constipation severity. The questionnaire has a total score and three subscales: Abdominal Symptoms, Rectal Symptoms, and Stool Form. The mean total score and each of the scale subscores are reported in a range of 0-4, with higher scores meaning worse outcomes. A difference (number) of 0.75 in the mean PAC-SYM total and each of the subscale scores is regarded as a clinically significant change. (NCT02609607)
Timeframe: Baseline, 4 weeks

,
Interventionunits on a scale (Mean)
Change in PAC-SYM Total ScoreChange in Abdominal SymptomsChange in Rectal SubscaleStool Subscale
Bisacodyl0.060.13-0.42-0.05
Placebo-0.24000

[back to top]

Change From Baseline in SF-36 Scores at 4 Weeks

The RAND Health Survey (v.1) is a 36 item questionnaire that measures health in multiple domains. The measure is reported as scores on eight subscales: Physical functioning, Role limitations due to physical health, Role limitations due to emotional problems, Energy/fatigue, Emotional well-being, Social functioning, Pain, and General health. Scores on each subscale range from 0 and 100, with higher scores indicative of better health function in the domain. (NCT02609607)
Timeframe: Baseline, 4 weeks

,
Interventionunits on a scale (Mean)
Physical functioningRole limitations due to physical healthRole limitations due to emotional problemsEnergy/fatigueEmotional well-beingSocial functioningPainGeneral health
Bisacodyl-1.25-12.516.5-6.25-10-1.75-3.75
Placebo3.33-16.67-7.33-4.17-5.33-4.513.67-4.17

[back to top]

Change From Baseline in Fecal Incontinence Quality of Life (FIQL) Score at 4 Weeks

The Fecal Incontinence Quality of Life (FIQL) Scale measures of the impact of fecal incontinence on aspects of quality of life. There are 4 subscales: Lifestyle, Coping/Behavior, Depression/Self-Perception, and Embarrassment, each of which is calculated as an average score ranging from 1 to 5, with higher scores indicating a greater functional status of quality of life. (NCT02609607)
Timeframe: Baseline, 4 weeks

,
Interventionunits on a scale (Mean)
LifestyleCoping / BehaviorDepression/ Self-PerceptionEmbarrassment
Bisacodyl-0.1-0.060.070.17
Placebo-0.32-0.22-0.17-0.44

[back to top]

Change From Baseline In Percent of Subjects With Normal Average Stool Form at 4 Weeks

The Bristol Stool Scale (BSS) is a validated measure of stool form, ranging from 1-7. Normal stool form is regarded as average scores of 3 to 4. Subjects were asked to assess the BSS in their 'bowel diaries' during a preparatory phase of up to 4 weeks prior to study entry and for 4 weeks after intervention, but these 'bowel diaries' were not required for entry into the trial. (NCT02609607)
Timeframe: Baseline, 4 weeks

Interventionpercentage of participants (Number)
Placebo0
Bisacodyl0

[back to top]

Change From Baseline in PAC-QOL Scores at 4 Weeks

The Patient Assessment of Constipation Quality of Life (PAC-QOL) Questionnaire is a validated measure of the quality of life impact of constipation. The questionnaire is reported a total score, reported as the average item scores and ranging from 0 to 4, where higher scores represent poorer QOL. (NCT02609607)
Timeframe: Baseline, 4 weeks

Interventionunits on a scale (Mean)
Placebo-0.04
Bisacodyl-0.33

[back to top]

Change From Baseline in Fecal Incontinence Severity Index (FISI) Score at 4 Weeks

The Fecal Incontinence Severity Index (FISI) is measures of fecal incontinence severity. The FISI score ranges from 0 to 61, with higher scores interpreted as worse fecal incontinence severity. (NCT02609607)
Timeframe: Baseline, 4 Weeks

Interventionunits on a scale (Mean)
Placebo-1.83
Bisacodyl4.25

[back to top]

Change From Baseline In Average Number of Fecal Incontinence Episodes at 4 Weeks

Subjects were asked to record each episode of fecal incontinence in their 'bowel diaries' during a preparatory phase of up to 4 weeks prior to study entry and for 4 weeks after intervention. We used this information to calculate the mean difference in the average number of fecal incontinence episodes / day. (NCT02609607)
Timeframe: Baseline, 4 weeks

Interventionincontinence episodes per day (Mean)
Placebo0.05
Bisacodyl-0.04

[back to top]

Number of Participants With 30% Improvement From Baseline in Bowel Symptoms at 4 Weeks

"All subjects were asked the following question at study entry ('baseline') and the end of 4 weeks of intervention: Using a scale of 1 to 10 (1 being no problem and 10 being maximally impactful symptoms), how would you rate the severity of your bowel symptoms over the past 2 weeks?~The range of reported values was 2-9. We took a response to be a 30% decrease (i.e. improvement) in the subjective symptom score between the baseline and 4 week assessment." (NCT02609607)
Timeframe: Baseline, 4 weeks

InterventionParticipants (Count of Participants)
Placebo2
Bisacodyl0

[back to top]

Change From Baseline In Average Number of Daily Bowel Movements at 4 Weeks

Subjects were asked to record each bowel movement in their 'bowel diaries' during a preparatory phase of up to 4 weeks prior to study entry and for 4 weeks after intervention. We used this information to calculate the average difference in number of bowel movements / day before and after exposure to placebo or Bisacodyl. However, these 'bowel diaries' were not required for entry into the trial. Thus, comparative data for bowel movement frequency was available for 3 of the 6 subjects randomized to placebo, and 2 of the 4 subjects randomized to receive Bisacodyl. (NCT02609607)
Timeframe: Baseline, 4 weeks

Interventionbowel movements per day (Mean)
Placebo0.02
Bisacodyl-0.21

[back to top]

Average Daily Opioid Requirement [in IV Fentanyl Equivalents (mcg Per Day)]

Average daily opioid requirement is converted to IV fentanyl equivalent listed in mcg per day (NCT02977286)
Timeframe: From randomization to ICU discharge or a maximum of 10 ICU days

Interventionmcg per day (Mean)
Naloxegol Oral Tablet1420
Placebo Oral Tablet1600

[back to top]

Daily Difference in the Pre-dose and Post-dose Clinical Opioid Withdrawal Scale (COWS) Score

Patients were evaluated 1 hour before and 2 hours after the administration of each dose of study medication using the Clinical Opioid Withdrawal Scale (COWS). COWS is used to help determine the stage or severity of opiate withdrawal and assess the level of physical dependence on opioids. The COWS score ranges from 0-36+. A score of 0 is no active opioid withdrawal. A score of 5-12 is mild; 13-24 is moderate; 25-36 is moderately severe and more than 36 is severe opioid withdrawal. (NCT02977286)
Timeframe: One hour before the daily study drug administration and 2 hours after the daily study drug administration

InterventionDifference of COWS score (Mean)
Naloxegol Oral Tablet-0.1
Placebo Oral Tablet0.2

[back to top]

Daily Fluid Balance

Daily fluid balance measured in mL is the 24 hours ins and outs (NCT02977286)
Timeframe: From randomization to ICU discharge or a maximum of 10 ICU days

InterventionmL (Mean)
Naloxegol Oral Tablet-338
Placebo Oral Tablet-210

[back to top]

Daily Maximal Pain Scale Score

"Based on the highest daily Visual Analogue Scale-10 or Clinical Pain Observation tool assessment.~VAS-10 is Visual Analogue Scale which uses a nurse-administered 10 point rating scale. A measurement of 0-1 is minimal pain. A measurement of 10 is severe pain." (NCT02977286)
Timeframe: From randomization to ICU discharge or a maximum of 10 ICU days

Interventionscore on a scale (Mean)
Naloxegol Oral Tablet0
Placebo Oral Tablet0

[back to top]

Daily Maximal Sedation Assessment Scale (SAS) Score

"The Sedation Assessment Scale is rated 1 to 7. Score of 7 is dangerous agitation. Score of 1 is unarousable. Score of 2 is very sedated. The presence of coma is based on the every 4 hour sedation agitation score scale (SAS) assessment. A score of 1 or 2 any time during the day represents that a coma is present. A score of 3-7 represents a subject with no coma present.~Results listed here is days without coma (SAS score of 3-7)" (NCT02977286)
Timeframe: From randomization to ICU discharge or a maximum of 10 ICU days

Interventiondays (Median)
Naloxegol Oral Tablet3
Placebo Oral Tablet7

[back to top]

Daily Presence of Delirium Using the Intensive Care Delirium Screening Checklist (ICDSC)

Measures as days without delirium with daily presence of delirium assessed using the Intensive Care Delirium Screening Checklist (ICDSC) (NCT02977286)
Timeframe: From randomization to ICU discharge or a maximum of 10 ICU days

Interventiondays without delirium (Median)
Naloxegol Oral Tablet5
Placebo Oral Tablet6

[back to top]

Days Without Mechanical Ventilation Support for Duration of ICU Stay

Measure is days without mechanical ventilation for duration of ICU stay as expressed as median and inter-Quartile Range (NCT02977286)
Timeframe: From ICU admission to ICU discharge or a maximum of 10 ICU days

Interventiondays (Median)
Naloxegol Oral Tablet0.5
Placebo Oral Tablet1

[back to top]

ICU Days Without a SBM

Measured ICU days that subjects did not have a SBM (NCT02977286)
Timeframe: During period of ICU admission or a maximum of 10 ICU days

InterventionDays (Mean)
Naloxegol Oral Tablet2
Placebo Oral Tablet2

[back to top]

Abdominal Pressure Measurement

On days when the patient had a urinary catheter in place for clinical reasons, a bladder pressure transducer was inserted and abdominal pressure was measured. The average daily maximum pressure score for each group is reported. (NCT02977286)
Timeframe: From randomization to ICU discharge (or removal of foley catheter) or a maximum of 10 ICU days

InterventionmmHg (Mean)
Naloxegol Oral Tablet10
Placebo Oral Tablet13

[back to top]

Number of Patients With Loose and Unformed or Liquid SBM

Consistency of SBM is characterized in one of 4 categories: hard and formed, soft but formed, loose and unformed, and liquid. The number listed in the results section is the number of patients who had either loose or liquid SBM (as opposed to hard or soft formed). (NCT02977286)
Timeframe: From randomization to ICU discharge or a maximum of 10 ICU days

InterventionParticipants (Count of Participants)
Naloxegol Oral Tablet5
Placebo Oral Tablet6

[back to top]

Occurrence of Lower GI Tract Paralysis (≥3 Days Without a SBM)

Measurement is the number of subjects in each group having this occurrence of lower GI tract paralysis during time frame (NCT02977286)
Timeframe: From randomization to ICU discharge or a maximum of 10 ICU days

InterventionParticipants (Count of Participants)
Naloxegol Oral Tablet2
Placebo Oral Tablet3

[back to top]

Occurrence of Lower GI Tract Paralysis Requiring GI/Surgical Consultation

Number of patients with GI tract paralysis requiring Gastroenterology service or Surgical service consultation (NCT02977286)
Timeframe: From randomization to ICU discharge or a maximum of 10 ICU days

InterventionParticipants (Count of Participants)
Naloxegol Oral Tablet0
Placebo Oral Tablet0

[back to top]

Percentage of Daily Goal Reached for Enteral Nutrition Administration

Enteral nutrition is assessed as daily volume in mL and the reported measure is the percentage of daily goal of enteral nutrition met. (NCT02977286)
Timeframe: From randomization to ICU discharge or a maximum of 10 ICU days

Interventionpercentage of daily goals met (Mean)
Naloxegol Oral Tablet54
Placebo Oral Tablet51

[back to top]

Time to First Episode of Diarrhea

The number of patients in each group with > or equal to 1 episode of diarrhea after initiation of study drug. The time to first episode of diarrhea was measured in hours. (NCT02977286)
Timeframe: Study drug initiation to first episode of diarrhea in hours.

Interventionhours (Median)
Naloxegol Oral Tablet40
Placebo Oral Tablet109

[back to top]

Time to First Spontaneous Bowel Movement (SBM)

Time to first spontaneous bowel movement during the ICU admission after opioid initiation (NCT02977286)
Timeframe: First occurrence after initiation of IV opioid therapy during period of ICU admission or a maximum of 10 ICU days

Interventionhours (Mean)
Naloxegol Oral Tablet52
Placebo Oral Tablet49

[back to top]

Time to First Spontaneous Bowel Movement (SBM) Administration

Time to first spontaneous bowel movement during ICU admission after randomization (NCT02977286)
Timeframe: First occurrence after study randomization during period of ICU admission or a maximum of 10 ICU days

Interventionhours (Mean)
Naloxegol Oral Tablet41
Placebo Oral Tablet33

[back to top]

Number of Patients That Required Use of the Study Laxative Protocol

A 4-step laxative protocol was initiated when there was no spontaneous bowel movement greater than or equal to 3 days time. Data collected on study laxative protocol included any use as well as the highest level needed. (NCT02977286)
Timeframe: From randomization to ICU discharge or a maximum of 10 ICU days

Interventionparticipants (Number)
Naloxegol Oral Tablet5
Placebo Oral Tablet4

[back to top]